

CURRICULUM VITAE

Personal Information:

Name: Cohen, Myron Scott
Phone: W: (919) 966-2536
Work Address: University of North Carolina at Chapel Hill
Division of Infectious Diseases
130 Mason Farm Rd.
Bioinformatics, 2nd Floor
Chapel Hill, NC 27599-7030

Education:

BS (Summa Cum Laude)	University of Illinois	1969-1971
MD	Rush Medical College	1971-1974
Internship	University of Michigan	1974-1975
Residency	University of Michigan	1975-1977
Infectious Disease Fellow	Yale University	1977-1980

Professional Experience - Employment History:

Yeargan-Bate Eminent Professor	7/1/13-present
Associate Vice Chancellor for Medical Affairs	7/1/07-present
Director, Institute of Global Health and Infectious Disease	7/1/07-present
Professor of Epidemiology, University of North Carolina	4/1/04-present
Director, UNC Center for Infectious Diseases	3/1/99-present
Professor of Medicine, Microbiology and Immunology	7/1/91-present
University of North Carolina at Chapel Hill	
Chief, Division of Infectious Disease, University of North Carolina at Chapel Hill	8/1/90-1/14/19
J. Herbert Bate Distinguished Professor	9/1/01-6/30/13
Sabbatical Scholar, London School of Hygiene and Tropical Medicine	2006
Sabbatical Scholar, Swiss Institute for Experimental Cancer Research; Lausanne, Switzerland	11/1/87-7/1/88
Associate Professor of Medicine, Microbiology and Immunology, University of North Carolina at Chapel Hill	7/1/85-6/30/91
Acting Director, Hospital Epidemiology, University of North Carolina at Chapel Hill	7/1/83-6/30/85
Assistant Professor of Microbiology and Immunology, University of North Carolina at Chapel Hill	7/1/80-6/30/85
Assistant Professor of Medicine, University of North Carolina at Chapel Hill	5/1/80-6/30/85

Certification and Licensure:

Medical Licenses

North Carolina	#24140
Michigan	(inactive)

Connecticut (inactive)

Certification

Diplomate, American Board of Internal Medicine, June 1977
Diplomate, Subspecialty of Infectious Disease, November 1982

Professional Societies:

American College of Physicians, Fellow
American Federation of Clinical Research
American Society for Microbiology
American Association for the Advancement of Science
Reticuloendothelial Society
Infectious Diseases Society of America, Fellow
Southern Society of Clinical Investigation
American Association of Immunology
American Society of Clinical Investigation
Association of Subspecialty Professors
American Clinical and Climatological Association
Association of American Physicians
Institute of Medicine, National Academy of Science
American Academy of Microbiology, Fellow

Special Honors & Awards:

Honorary Societies

Phi Eta Sigma	1969
Phi Beta Kappa (Junior Year)	1971
Alpha Omega Alpha (Junior Year)	1973

Honors

James Scholar Program, University of Illinois
American Medical Association Continuing Education Award
Jefferson Pilot Award
R.J. Reynolds Award
Rush Medical College Alumni Presentation, June 7, 1984
UNC Cofounders Day Presentation, October, 1984
Armen T. Wilson Orator, Delaware Academy of Medicine, May 9, 1985
W.H. Reynolds Award (Sabbatical leave, 1987-1988)
Fekety Lectureship, University of Michigan, 1998
Keynote Address, ISSTDR, Seville, Spain, 1998
Keynote Address, Australian STD Society, Adelaide, Australia, 1999
Distinguished Alumnus Award, Rush Medical College, May 1999
Keynote Address, The United Nations, World AIDS Day, December 1, 2000
America's Top Doctors, 2002-
America's Best Doctors, 2005-
Keenan Award, London School of Hygiene and Tropical Medicine, 2006
Lifetime Achievement Award, American Society of Venereal Diseases

NIH MERIT Award, 2005-2015
Class of 1943 Honorary Lecture, The University of Indiana, 2007
Keynote Address, CDC HIV Prevention Conference, Atlanta GA, Dec. 4, 2007
Keynote Address, The Eugene B. Mayer Society, UNC, Feb 21, 2008
O. Max Gardner Award, The University of North Carolina System, 2008
Keynote Plenary Lecture, IAS Mexico City, 2008
Keynote Address, State of North Carolina, World AIDS Day, 2008
“Great Teachers” Lecture, NIAID, March 11, 2009
Plenary Speaker, Keystone HIV Prevention Meeting, March 2009
Richard K Root Memorial Lecture, International Infectious Disease Society, March 2010
Special Plenary, ISSTDR, Quebec, July 2011
Hope is a Vaccine AWARD, GAIA, 2011
Science Magazine Breakthrough of the Year, 2011
Katerva Award Sustainable Development (Finalist), 2011
Triangle Business Journal Lifetime Achievement Award, 2011
Leo M Evers Memorial Lecture, NYU, 2011
Andrew Kaplan Memorial Lecture, Retroviral Adherence Meeting, 2012
Herb Pardes Award, Clinical Research Forum, 2012
Association of American Physicians, Special plenary Lecture, 2012
Arthur Ashe Memorial Lecture, Cornell, 2012
Galkin Lecturer, Brown University, 2012
Dyer Lecture, The National Institute of Health, 2012
Keynote Address, Glasgow HIV Meeting, 2012
Commencement Speaker, University of North Carolina at Chapel, 2012
Special Citation, Infectious Disease Society of America, 2012
Tarheel of the Year, The Raleigh News and Observer, 2012
Keynote Address, Keystone HIV Vaccines, 2013
Smadel Lectureship Award, IDSA, 2013
Keynote address, HIV in the Americas, San Paolo Brazil, 2013
The North Carolina Award in Science, 2013 (the highest civilian honor in the State)
The UNC School of Medicine Berryhill Lecture, 2014
The UNC General Alumni Association Faculty Service Award, 2015
UNC School of Medicine Commencement Address, 2015
R4P Opening Plenary Lecture, 2016
Louis Weinstein Lecture at Tufts Medical University, 2017

Teaching Activities:

Yale School of Medicine

Director of Physicians Associates Studies, Department of Medicine, 1979-1980
Preceptor in Physical Diagnosis, 1979
Microbiology Course Director, Physicians Associate Program, 1977-1979

University of North Carolina School of Medicine

Residents Report 1980-
Lectures on Antimicrobial Agents to Medical Students
Lecturer in Bacteriology 120, 1981-
Lecturer in Immunology 114, 1981-
Lecturer in MEDS-PEDS 429, 1981-

Lecturer in Medical Microbiology for first-year medical students
Lecturer in Medical Immunology for first-year medical students
Lab Instructor in Medical Immunology for first-year students
Participation in Infectious Disease Clinical Conferences and Fellows Conference
University of North Carolina Annual Internal Medicine Symposium, 1980-
AHEC presentations, 1980-
Course Director (with Steven Haskill), Graduate immunology seminar in phagocyte structure and function, 1986

Educational Mentoring Activities:

Master's Thesis Advisor: Patty Leong, D.D.M., Rachel Davis, Marie-Christine Piriou

Ph.D. Thesis Co-Advisor: Susan Kaydos, Matthew Price, Kimberly Powers, Brook Levandowski, Lillian Brown, Kate Muessig, Zhu Hao, Margaret Kumi Smith

Thesis Committees: Lynne Bristol, Ellen Ahoe, Sarah Sporn, John Woods, Marcia Hobbs, Linda Levin, Dianna Johanson, Richard Pierce, Wilfrida Behets, Nan Guyer, Jan Deese,

Postdoctoral Fellows: Bradley E. Britigan, M.D. (Infectious Diseases)
Rose G. Snipes, M.D. (Endocrinology)
Susan Saviteer, M.D., MPh. (Epidemiology)
Kai-Song Fu, (Microbiology)
Geetha Sivam, M.D. (Endocrinology)
Blonnie Thompson, Ph.D. (Immunology)
Sovitj Pou (Organic Chemistry)
Daniel Hassett, Ph.D. (Microbiology)
Robert D. Weber (Infectious Diseases)
Mao Jingh, MD (Microbiology)
Jon Serody, MD (Infectious Diseases)
Tim Alcorn, PhD (Microbiology)
Zheng Heyi, MD (Microbiology)
Michael Gunther, PhD (Microbiology)
Susan Isbey, MD (Infectious Diseases)
Kimberly Fox, MD (Infectious Diseases)
Arlene Seña, MD (Infectious Diseases)
Srilatha Edupuganti, MD (Infectious Diseases)
Michael Blocker, MD (Infectious Diseases)
Heidi Swygard, MD, MPH (Infectious Diseases)
Shannon Galvin, MD (Infectious Diseases)
Cynthia Gay (Infectious Diseases)

Medical Students Cindi Hall, John Sheline, Doug Mesler, Paige Wallend, Julie Haizlip, Sabina Shu, William Fischer, Joe Tucker

NIH F32 Lillian Brown, Kate Muessig

Undergraduates	Karen Bean, Vicky Richardson, Pamela Yount
Visiting Scholars	Yaachov Chai, Israel Institute for Biological Research Tanwer Syed Ahmed, Department of Physiology Lund University, Malmö University Hospital, Sweden Hemant Kulkarni, MD, University of Nagpur, India Alvaro Pascual, MD, University of Seville, Spain Rebecca Baggaley (LSHTM)
NIH (K23)	Holly Jordan, Angela Kashuba, Jennifer Webster-Cyriaque, Mina Hosseinipour, Alex Duncan, Joseph Tucker
ATPMH	Joseph Tucker (Harvard)
Welcome Trust	Rebecca Baggaley (TSTMH)
NIH Re-entry	Kristine Torjeson

Grants Funded:

American Cancer Society Institutional	IN-1520
Jefferson-Pilot Award	1982-1986
NIH Award A15036	Phagocyte Defenses at the Mucosal Surface, 1983-1988, 1988-1991.
Cystic Fibrosis Foundation Grant	Pathogenesis of Pseudomonas Infection in CF-RSG (Component 2) Cystic Fibrosis. 1988-1989
NIH Award I-ROI AM33200	Vitamin D, Calcium Metabolism and Phagocytic Cells (with T.K. Gray, M.D.) 1983-1986. Renewal 1987-1990
NSF Award DCB-8616115	Application of Spin Trapping to Phagosomal Events. 1987-1990, 1991-1992
NIH Award AI23939	Phagocytes, Free Radicals and Cellular Consequences. 1988-1993
NIH Award U01AI31496	UNC-NIH Cooperative STI Research Center Core Lab Director, P.I. - M.S. Cohen. Project 3 - A human challenge study of <i>N. gonorrhoeae</i> , 1991-1994, 1994-99, 1999-2004.
NIH Award AI13496	UNC STI Cooperative Research Center 2004-2009 Project 1-STD and HIV-Co-transmission
Agency for International Development	AIDSCAP, STD Subcontract, P.I. - M.S. Cohen 1992-1996, Project IMPACT Cooperating Partner, 1997-2002, 2002-2007

NIH Award RO1 DK49381	HIV in Semen - Effects of STDs and antiviral agents, 1996-1999, 2000
NIH MERIT Award R37 DK49381	HIV in Semen- Effects of STDS and antiviral agents, 2005-2015
NIH R01 DK 108424	The Compartmental Biology of HIV, 2015-2020
NIH STD-CTU NO1-AI-75329	PI, 1997-2006
NIH HIVNET AI-3517-3412	PI, 1997-2002
NIH HPTN AI-40085	Executive Committee, 1999-2013
NIH HPTN AI 40085	Co-PI, 2012-2021
UNC NIH Center for AIDS Research	Associate Director 1997-2000, 2000-2005, 2006-2011, 2011-15, 2015-2020
NIH Center for HIV Immunology	Director Core B, Senior Leadership Group 2005-2012
NIH Training Grant AI07151	Pathogenesis of Infectious Disease Preceptor 1980-present, PI, 2000-2010
NIH Training Grant AI07001	Sexually Transmitted Diseases Preceptor 1980- present
NIH Fogarty Training Center	Training for HIV/STD Research 1998- 2003, 2004-2009, 2010-15: Co-Director
Jackson Foundation	STD Control RV81, 1994-1999
USAID TASC3	2007-2012
ATPM STD Preventive Medicine Fellowship, PI 1995 (Kimberly Fox)	
ATPM STD Preventive Medicine Fellowship, PI 1996 (Arlene Sena)	
ATPM STD Preventive Medicine Fellowship, PI 1997 (M. Blocker)	
ATPM STD Preventive Medicine Fellowship, PI 2001 (A. Edozien)	
ATPM STD Preventive Medicine Fellowship, PI 2004 (Cindy Gay)	
<u>Sponsored Awards</u>	
Rose G. Snipes	The American Kidney Fund Award, 1983 The Carolina Program for the Minorities, 1984-1986
Bradley Britigan	The Burroughs Wellcome Award of the Infectious Disease Society of America, 1985-87

	The American Society for Microbiology, Travel Scholarship
Douglas Mesler	The Kuomo Award for Outstanding Student Research, UNC School of Medicine
Patricia Leong	Student Research Award 1983, UNC School of Dentistry
R.D. Weber	National Research Service Award, HIV and Monocytic Phagocytes, 1989-1991
J. S. Serody	National Research Service Award, Phagocyte Cells and Free Radical Biology - 1991-92
Susan Isbey	National Rosen Service Award, LOS of <i>N. gonorrhoeae</i> 1995-96
K. Bean, V. Richardson, P. Yount	NSF Research Experience for Undergraduates
Charles Lin (UCSF) 2005	NIH Ellison Fellowship (China)
Susan Wong (Pittsburgh) 2006	NIH Ellison Fellowship (China)
Kate Muessig (Johns Hopkins) 2007	NIH Ellison Fellowship (China)
Rachel Pearline (Tulane) 2008	NIH Ellison Fellowship (China)
Matt Robinson (Northwestern) 2009	Doris Duke Fellowship (China)
Jia Ji (Ohio State) 2008	NIH Ellison Fellowship (China)
Helena Chang (Wisconsin) 2009	NIH Ellison Fellowship (China)
Joseph Tucker (Harvard) 2006-	NIH Fogarty Fellow, ASTPH Award (China)
Kai Sun (Washington, SL) 2009-10	Doris Duke (China)
Ben Wang (UCSF) 2010-11	Doris Duke (China)
Alberta Chang (Baylor) 2010-11	NIH Ellison Fellowship (China)

Professional Service:

Editorial Board

Infection and Immunity	1980-85, 1990-1995
Current Therapeutic Topics, UNC	1983-1986
Infections in Medicine	1985-2000
Clinical Reviews of Microbiology (Guest Editor)	April 1989
Sexually Transmitted Diseases	1995
Post Graduate Medicine (Guest Editor)	Sept 1995 STDS and HIV
Chinese Journal of Sexually Transmitted Diseases	2004-
Current Opinion in HIV and AIDS	2005-

UP to DATE (STDs) 2002-
Journal of Infectious Disease 2006-
JAIDS 2007-

Editor

Sexually Transmitted Diseases, Associate Editor 2004-

Reviewer

American Journal of Medicine
American Journal of Cell Physiology
Annals of Internal Medicine Blood
Archives of Internal Medicine
Archives of Biochemistry & Biophysics
Blood
Clinical Research (Abstracts)
International Journal of Cancer
Institute of Medicine Reports
Journal of Biological Chemistry
Journal of Clinical Endocrine and Metabolism
Journal of Clinical Investigation
Journal of Immunology
Journal of Infectious Diseases
Journal of Leukocyte Biology
Journal of Pediatrics
Kidney International
Molecular Pharmacology
New England Journal of Medicine
Nature Immunology
Lancet

Committees (Selected):

UNC School of Medicine

Pharmacy and Therapeutics, 1980-2000
Ad Hoc Committee on the Clinical Oncology Faculty, 1979-1985
Committee on the Evaluation of the Clinical Microbiology Training Program, 1979-
University Committee on UNC-China Exchange Programs, 1979-
N.C. Memorial Intensive Care Committee, 1983-1985
UNC School of Medicine Faculty Awards Committee, 1983-1987
UNC Medical Science Lecture Committee, 1984-, Chairperson 1990-
UNC Faculty Council, 1985-1988
UNC Committee on Research, 1987-1990
Clinical Cancer Program Advisory Committee, 1989-1995
Ad Hoc Committee, Comprehensive Cancer Center
Chancellor's Task Force on AIDS, State of North Carolina, 1994
Chairman, North Carolina Medical Society STD & AIDS Committee, 1985-1990
Member, State Health Committee on AIDS 1999-2003
President, North Carolina Infectious Diseases Society 2001-2002
Director, UNC Mini-Medical School, 1999-2002

Dean's Advisory Committee, 1999-

Grant and Awards Review Committees

Awards Committee, Rush Medical College, 1985-1990
Ad Hoc Reviewer, Veterans Administration Career Development and Merit Review Awards
Welcome Foundation Review Committee, Ad Hoc Reviewer
Ad Hoc Reviewer, NIAID
Ad Hoc Reviewer, National Science Foundation
Chairperson, NIH Ad hoc Study Section: NCDDG for the Treatment of AIDS, 1990-92
Ad Hoc Reviewer, U.S. Department of Agriculture
Chairperson, NIH ACTG Review for Opportunistic Infections, 1991
Veterans' Administration Infectious Disease Research Review Committee, 2001-
Ad Hoc Reviewer, Fogarty AITRP, 2003-
NIH MIDRC Study Section, 2004, 2005
Chairperson, NIH HIT-IT Study Section, April, 2009

Meeting Planning Committees

Chairperson, Free Radical Workshop, 8th Annual International Congress of Immunology, Budapest.
Director, Keystone Symposium, April 17-23, 1995; STDs in the HIV Era
Scientific Program Committee, International Society for STD Research, New Orleans, 1995
Scientific Program Committee, International Pathogenic Neisseria Conference, Baltimore, MD, 1996
Scientific Program Committee, International Society for STD Research, Seville, Spain, 1997
ISSTDR Planning Committee, 1998-2005
Program Committee, Infectious Disease Society of America, 2001-2004
Program Committee, 8th World STI/STD Congress, Uruguay, SA.
Organizer, First Sino-American HIV Research Meeting, Beijing, China, 2002
HIV Transmission Prevention, Toronto, Canada (Co-Chair) 2006
CDC HIV Testing, Washington DC, 2007
IAS Australia Program Committee
Gates Foundation HIV Prevention, Washington DC (Co-Chair) 2007
ASM HIV Drug Resistance Initiative (Chair)

National and International Committees

Institutional Representative, The American Federation for Clinical Research, 1980-1990
Counselor, American Federation for Clinical Research (Southern Region), 1986-1989
Chairperson, Infectious Disease Subsection, ASCI, 1989
American College of Physicians; MKSAP10 (Infectious Diseases)
CDC Review Committee, 1994
NIAID Mucosal Immunology Think Tank, Washington DC, participant, 1997
IDSA Training Program Committee, 1997-2000
HIVNET Vaccine Development Committee, 1997
Fogarty Workshop Steering Committee, 1998
IDSA Editor Search Committee-Clinical Infectious Diseases, IDSA, 1999
USF International HIV Prevention Committee, 1998
Board of Directors, ISSTDR, 1999-2005
Member, Institute of Medicine Committee on HIV Prevention Strategies, 1999-2000
HIVNET (HPTN) ART Working Group Chair, 1999-
CDC STD Guidelines, 2000

CDC ART Research Working Group, 2000
Office of AIDS Research International Advisory Committee, 2001-
CDC Postexposure Prophylaxis Guidelines Committee, 2001
IDSA Program Committee 2002-2005
China CIPRA Advisory Board Chair 2002-2007
Advisory Board, Institute of Human Virology (UM), 2009-2014
Advisory Board, Harvard AIDS Institute, 2005
Member, Institute of Medicine Committee on Gulf War Infections, 2005-2006
CDC HIV Prevention Advisory, 2005
USPH-IDSA HIV Prevention Guidelines, 2007
SAB, Emory University CFAR, 2007-2010
SAB, University of Cincinnati CFAR, 2007
HIV Transmission Meeting Board, 2009-
IAS Capetown Track C Co-Chair, Scientific Planning Committee, 2009
Chair, Genome Wide Association and HIV Acquisition, OAR, NIH 2009
CDC External Advisory Committee, April 2009
CDC Review Panel, Detection of AHI, April 2009
AIDS 2013 Advisory Committee, Lancet Special Issue, 2010
WHO HIV Ad Hoc Advisory Committee, 2011
CDC HIV Ad Hoc Advisory Committee, 2012
UNAIDS Science Panel, 2013-
R4P Program Committee 2013-
Imperial College Infectious Disease/MRC ID Modeling Advisory Board, 2014-
University of Pennsylvania, Mental Health AIDS Research (PMHARC) Advisory Committee, 2014-
IAS Program Committee, 2015
Northwestern University SLAP Executive Committee, 2015-
QURA UNC/GSK Joint Venture, Board of Directors, 2015-
PANGEA BMGF Collaboration Advisory Board, 2017-
McGill University Center for Global Health Advisory Board, 2018-
Fogarty International Center Advisory Board, 2018-
China CDC International Consultant Committee for Global Public Health, 2018-
National Academy of Medicine Global Health, Infectious Diseases, Microbiology Committee (Vice chair), 2021

US Government Advisory Committees

NIH AIDS Research Advisory Committee 2011-2014
PEPFAR Scientific Advisory Board 2011-
NIH Office of AIDS Research 2011-2014
NIAID Board of Scientific Counselors (ad hoc) 2015
NIH Fogarty International Center Advisory Board 2018-
NIH ACTIV Clinical Trials Working Group 2020-
NIAID CoVPN 2020-

Board of Directors

Qura UNC/GSK Joint Venture 2015-
UNC Global Projects, LLC

Bibliography and scholarship:

Articles in peer-reviewed journals (chronological order)

1. **Cohen MS**, Brook CJ, Naylor B, Plouffe J, Silva J, and Weg JG. Pulmonary phycomycetoma in a patient with diabetes mellitus. *Am Rev Resp Dis* 116:519-523, 1977.
2. **Cohen MS** and Walker S. The nervous system in systemic lupus erythematosus. *Mich Med J* 44(2):65-69, 1978.
3. **Cohen MS**, Steere AC, Baltimore R, Von Graevenitz A, Pantelick E, Camp B, and Root RK. Possible nosocomial transmission of Group Y *Neisseria meningitidis* among oncology patients. *Ann Int Med* 91:7-13, 1979.
4. **Cohen MS**, Zakhireh B, Metcalf JA, and Root RK. Granulocyte function during lithium therapy. *Blood* 53:913-915, 1979.
5. Zakhireh B, Thakur ML, Malech HL, **Cohen MS**, Gottschalk A, and Root RK. *In vitro* evaluation of Indium-111 labeled neutrophils. *J Nuclear Med* 20:478-753, 1979.
6. **Cohen MS**, Metcalf JA, and Root RK. Regulation of oxygen metabolism in human granulocytes: Relationship between stimulus binding and oxidative response. *Blood* 55:1003-1010, 1980.
7. **Cohen MS**, Ryan JL, and Root RK. The oxidative metabolism of thioglycollate elicited mouse peritoneal macrophages: The relationship between oxygen, superoxide and hydrogen peroxide. *J Immunol* 127:1007-1011, 1980.
8. **Cohen MS**, Isturiz RE, Mallech HL, Root RK, Wilfert CM, Gutman L, and Buckley RH. Fungal infection in chronic granulomatous disease: The importance of the phagocyte in defense against fungi. *Am J Med* 71:59-67, 1981.
9. **Cohen MS**, Casals G, Hsiung GD, Kwei H, Chin C, Ge H, Hsiang C, Lee PW, Gibbs CJ, and Gajdusek DC. Epidemic hemorrhagic fever in Hubei Province, The People's Republic of China: A clinical and serological study. *Yale J Biol Med* 54 (1):51-55, 1981.
10. Finkelstein E, Rosen GE, Patton S, **Cohen MS**, and Rauckman EJ. Effect of modification of cytochrome c on its reactions with superoxide and NADPH: Cytochrome P-450 reductase. *Biochem Biophys Res Comm* 102:1008-1015, 1981.
11. Henderson GE and **Cohen MS**. Are biomedical exchange programs inside the People's Republic of China feasible? Report of a six month study at Hubei Provincial Medical College. *Yale J Biol Med* 54(1):11-20, 1981.
12. **Cohen MS**. After the Revolution: Medicine in China. *American College of Physicians Observer* I, p. 1, 1981.
13. **Cohen MS**, Peacock Jr. JE, Ross DW, and Boxer L. Automated cytochemical staining in the detection of Chediak-Higashi neutrophils. *J Infect Dis* 145:771, 1982.
14. **Cohen MS**, Taffett S, and Adams DO. The relationship between competence for secretion of H₂O₂ and completion of tumor cytotoxicity by BCG-elicited murine macrophages. *J Immunol* 128:1781-1785, 1982.
15. Peacock Jr. JE, Ross DW, and **Cohen MS**. Automated cytochemical staining and inflammation. Further assessment of the "left shift". *Am J Clin Path* 78:445-449, 1982.
16. **Cohen MS**, Shirley PS, and DeChatelet LR. Further evaluation of luminol enhanced luminescence in the diagnosis of disorders of leukocyte oxidative metabolism: Role of myeloperoxidase. *Clin Chem* 29:513-515, 1982.
17. **Cohen MS**, Elliott DM, Pike M, Chaplinski T, and Nidel J. A defect in the oxidative metabolism of human PMNs harvested during hemodialysis: Further evidence for a neutrophil subpopulation. *Blood* 60:1283-1289, 1982.
18. DeChatelet LR, Long GD, Shirley PS, Bass DA, Thomas MM, Henderson FW, and **Cohen MS**. Mechanism of the luminol-dependent chemiluminescence of human neutrophils. *J Immunol* 129:1589-1593, 1982.
19. Parmalee DE, Henderson GE, and **Cohen MS**. Medical practice in Yugoslavia and China: Comparison and contrasts. *Social Science and Medicine* 15:1389-1397, 1982.

20. Henderson GE and **Cohen MS**. Health care delivery in the People's Republic of China: A view from inside the system. *Am J Public Health* 72:1238-1246, 1982.
21. Peacock Jr. JE, Folds J, Orringer G, Luft B, and **Cohen MS**. *Toxoplasma gondii* and the compromised host: Antibody response in the absence of clinical manifestations of disease. *Arch Int Med* 143:1235-1237, 1983.
22. **Cohen MS**, Cooney MH, Blackman E, and Sparling PF. *In vitro* susceptibility of penicillin-sensitive and penicillin-resistant *Neisseria gonorrhoeae* to third generation cephalosporins. *Antimicrob Agents Chemother* 24:597-599, 1983.
23. **Cohen MS** and Henderson GE. The Chinese Hospital. *Ann Int Med* 99:564-565, 1983.
24. **Cohen MS** and Henderson GE. Medical care in the People's Republic of China: Available but expensive. *Ann Int Med* 99:727-728, 1983.
25. **Cohen MS**, Kwei HS, Chin CC, and Ge HC. Central nervous system manifestations of epidemic hemorrhagic fever: An advanced manifestation of disease associated with poor prognosis. *Arch Int Med* 143:2070-2077, 1983.
26. Tracy SL, McGinnis MR, Peacock Jr JE, **Cohen MS**, and Walker DH. Disseminated infection with *Aspergillus terreus*. *Am J Clin Path* 80:728-733, 1983.
27. **Cohen MS**, Walls S, Jaques PF, and Walker D. A fatal eosinophilic process in a Laotian refugee. *Am J Clin Path* 80:38-743, 1983.
28. Dodd RC, **Cohen MS**, Newman SL, and Gray TK. Vitamin D metabolites change the phenotype of monoblastic U937 cells. *Proc Natl Acad Sci USA* 80:7538-7541, 1983.
29. Poole MD, Postma D, **Cohen MS**. Pyogenic otorhinologic infections in acquired immune deficiency syndrome. *Arch Otorhinolaryng* 110:130-313, 1984.
30. Shafer WM, Joiner K, Guymon LF, **Cohen MS**, and Sparling PF. Serum sensitivity of *Neisseria gonorrhoeae*: Role of lipopolysaccharide. *J Infect Dis* 149:175-183, 1984.
31. **Cohen MS** and Gray TK. Phagocytic cells metabolize 25(OH)D₃ *in vitro*. *Proc Natl Acad Sci USA* 91:931-934, 1984.
32. Black JR and **Cohen MS**. Gonococcal osteomyelitis: A case report and review of the literature. *Sex Trans Dis* 11:96-99, 1984.
33. **Cohen MS** and Cooney MH. A bacterial respiratory burst: Human serum stimulates the oxidative metabolism of *Neisseria gonorrhoeae*. *J Infect Dis* 150:49-57, 1984.
34. Leone PA, Schwab JS and **Cohen MS**. Interaction of the peptidoglycan-polysaccharide complex of the cell wall of *Group A* streptococci and human polymorphonuclear neutrophils: Potential mechanisms for chronic inflammation and infection. *Infect Immun* 45:160-165, 1984.
35. Peacock JE, McGinnis MR, and **Cohen MS**. Persistent neutrophilic meningitis: Report of four cases and a review of the literature. *Medicine* 63:379-395, 1984.
36. Leong PA, Schwab JH, **Cohen MS**. Group A streptococcal peptidoglycan-polysaccharide inhibits the bacterial activity of human polymorphonuclear leukocytes. *Infect Immun* 45:160-165, 1984.
37. **Cohen MS**, Barranco SF, and Washton HE. A multicenter trial of cefoperazone in the therapy of bacterial infection in the United States. *Am J Med* 77:35-41, 1984.
38. Dodd RC, Newman SL, Bunn PA, Winkler CF, **Cohen MS**, and Gray TK. Lymphokine induced differentiation as a possible mechanism for hypercalcemia associated with adult T-cell lymphoma. *Cancer Res* 45:2501-2506, 1985.
39. Britigan BE and **Cohen MS**. Effect of growth in serum on uptake of *Neisseria gonorrhoeae* by human neutrophils. *J Infect Dis* 152:330-8, 1985.
40. Britigan BE, Chai Y, and **Cohen MS**. Metabolic, structural, and pathogenic changes of *Neisseria gonorrhoea* exposed to human serum: An alternative view of the interaction between bacteria and the host. In: *The Pathogenic Neisseria*. G.K. Schoolnick (ed.), ASM, Washington, D.C., p. 445-452, 1985.
41. **Cohen MS**, Leone PA, Simpson DM. Phagocytic cells and periodontal disease: Periodontal status of patients with chronic granulomatous disease in childhood. *J Periodontology* 56:611-617, 1985.

42. Gray TK, Millington D, **Cohen MS**, Williams ME, and Dodd RC. Identification of 19-nor, 10-keto 25(OH)D by mass spectrometry as a principle phagocyte derived metabolite. *Proc Natl Acad Sci USA* 82:8218-8221, 1985.
43. Britigan BE, Chai Y, and **Cohen MS**. Effects of human serum on the growth and metabolism of *Neisseria gonorrhoeae*: An alternative view of serum. *Infect Immun* 50:738-744, 1985.
44. Snipes RG, Lam KW, Dodd RC, Gray TK, and **Cohen MS**. Acid phosphate activity in mononuclear phagocytes and the U937 cell line: Monocyte-derived macrophages express tartrate-resistant acid phosphatase. *Blood* 67:729-734, 1986.
45. **Cohen MS**, Mesler DE, Snipes RG, and Gray TK. 1,25-dihydroxyvitamin D₃ activates H₂O₂ secretion by human monocytes. *J Immunol* 136:1049-1053, 1986.
46. Britigan BE, Rosen GM, Chai Y, and **Cohen MS**. Do human neutrophils make hydroxyl radical? Determination of free radicals generated by human neutrophils activated with a soluble or particulate stimulus using electron paramagnetic resonance spectrometry. *J Biol Chem* 261:4426-4431, 1986.
47. Britigan BE and **Cohen MS**. Effects of human serum on bacterial competition with neutrophils for molecular oxygen. *Infect Immun* 52:657-663, 1986.
48. Britigan BE, Thompson BY, Chai J, Rosen GM, and **Cohen MS**. Stimulated human neutrophils limit iron catalyzed hydroxyl radical formation as detected by spin trapping techniques. *J Biol Chem* 261:17026-17052, 1986.
49. Gray TK, D'Amico C, Kaplan R, Dodd RC, Mesler D, and **Cohen MS**. Mononuclear phagocytes secrete a protein that resorbs devitalized bone particles. *Bone and Mineral Res* 1:235-245, 1986.
50. Gui X-E, Ho M, **Cohen MS**, Wang Q-L, Huang HP, Xie Q-X. Hemorrhagic fever with renal syndrome: Treatment with recombinant interferon alpha. *J Infect Dis* 155:1047-1051, 1987.
51. Snipes RG, Ways K, D'Amico CN, Sivam G, Gray TK, and **Cohen MS**. The metabolite 1,25-dihydroxyvitamin D₃ enhances lymphokine-mediated activation of the oxidative metabolism of the U937 cell line and phosphorylation of a 48kD respiratory burst-associated protein. *Blood* 70:1639-1644, 1987.
52. Sivam G, **Cohen MS**, Dodd KC, and Gray TK. 17-Beta-Estradioal inhibits oxidative metabolism of the U937 cell indirectly via its action on lymphocytes. *Endocrinol* 121:853-857, 1987.
53. Weiner RE, **Cohen MS**, and Hoffer PB. Influence of various factors on labeling of polymorphonuclear leukocytes with GA-67. *Nucl Med Biol* 14:523-528, 1987.
54. **Cohen MS**, Chai Y, Svendsen TD, McKenna WR, and Britigan BE. Role of extracellular iron in the action of the guanine antibiotic streptonigrin on the killing of *Neisseria gonorrhoeae*: Mechanisms of action and resistance. *Antimicrobial Agents Chemother* 31:1507-1513, 1987.
55. **Cohen MS**, Britigan BE, French M, and Bean K. Lactoferrin secretion in human vaginal mucus: Variation during the menstrual cycle and implications for gonococcal infection. *Am J Obstet Gynecol* 157:1122-1125, 1987.
56. Gray TK, Kleckner NW, Malloy PJ, Feldman D, Sivam G, Dodd RC, and **Cohen MS**. Biological activity of 19-nor, 10-keto, 25-hydroxyvitamin D₃. *J Bone and Mineral Res* 2:413-420, 1987.
57. Hassett DJ, Britigan BE, Svendsen T, Rosen GM, and **Cohen MS**. Bacteria form intracellular free radicals in response to paraquate and streptonigrin: Demonstration of the potency of hydroxyl radical. *J Biol Chem* 262:13404-13408, 1987.
58. **Cohen MS** and Britigan BE. Metabolic response of *Neisseria gonorrhoeae* to human serum and myeloid cells: Adaptation to host defenses. *Anton Leeuwenhoek* 53:545-550, 1987.
59. Thompson B, Rosen GM, and **Cohen MS**. The O₂ metabolism of the HL-60 cell line: Comparison of the effects of monocytoid and neutrophilic differentiation. *J Leuk Biol* 43:140-147, 1988.
60. Britigan BE, Klapper D, Svendsen T, Bean K, and **Cohen MS**. Phagocyte derived lactate stimulates the metabolism of *Neisseria gonorrhoeae*: An unrecognized aspect of the O₂ metabolism of phagocytosis. *J Clin Invest* 81:318-324, 1988.
61. Rosen GM, Britigan BE, **Cohen MS**, Ellington SP, and Barber M. Detection of phagocyte-derived free radicals with spin-trapping techniques: Effects of temperature and cell metabolism. *Biochim Biophys Acta* 969:236-241, 1988.

62. Britigan BE, Coffman TJ, Adelberg DR, and **Cohen MS**. Mononuclear phagocytes have the potential for sustained hydroxyl radical production: Use of spin-trapping techniques to investigate mononuclear phagocyte free radical production. *J Exp Med* 168:2367-2372, 1988.
63. Britigan BE, Hassett DJ, Rosen GM, Hamill DR, and **Cohen MS**. Neutrophil degranulation inhibits potential hydroxyl-radical formation. *Biochem J* 264:447-55, 1989.
64. Weber RD, Britigan BE, Svendsen T, and **Cohen MS**. Energy is required for adherence of *Neisseria gonorrhoeae* to phagocytic and non-phagocytic cells. *Infect Immun* 57:785-790, 1989.
65. Cantoni O, Cattabeni F, Pou S, **Cohen MS**, and Cerutti P. Chelation of intracellular calcium ions prevents hydrogen peroxide induced DNA breakage and cytotoxicity. *European J Biochem* 192:209-212, 1989.
66. Fu K-S, Hassett DJ, and **Cohen MS**. Oxidant stress in *Neisseria gonorrhoeae*: Adaptation and effects on L(+)- lactate dehydrogenase activity. *Infect Immun* 57:2173-2178, 1989.
67. Pou S, Hassett DJ, Britigan BE, **Cohen MS**, and Rosen GM. Problems associated with spin trapping oxygen-centered free radicals in biological systems. *Analyt Biochem Anal Biochem* 177:1-6, 1989.
68. Rosen GM, Hassett DJ, Yankaskas JR, and **Cohen MS**. Detection of free radicals as a consequence of dog tracheal epithelial cellular xenobiotic metabolism. *Xenobiotica* 19:635-43, 1989.
69. Hassett DJ, Bean K, Biswas G, and **Cohen MS**. The role of hydroxyl radical in chromosomal and plasmid damage in *Neisseria gonorrhoeae* *in vivo*. *Free Rad Res Comm* 7:83-87, 1989.
70. Pou S, Rosen GM, Britigan BE, and **Cohen MS**. Intracellular spin trapping of O₂-centered radicals generated by human neutrophils. *Biochem Biophys Acta* 991:459-464, 1989.
71. Pou S, **Cohen MS**, Britigan BE, and Rosen GM. Human neutrophils and spin trapping: Limits of detection of hydroxyl radical. *J Biol Chem* 264:12299-12302, 1989.
72. Pegram PS, Phair JP, McMahan R, Murphy RL, Gordon LI, Washton H, Faubion C, Saviteer S, and **Cohen MS**. Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients. *J Antimicrob Chemother* 24:591-604, 1989.
73. Hassett DJ, Charniga L, and **Cohen MS**. *recA* and catalase in H₂O₂-mediated stress in *Neisseria gonorrhoeae*. *J Bacteriol* 172:7293-7295, 1990.
74. **Cohen MS**, Britigan BE, Chai YW, Pou S, Roeder TL, and Rosen GM. Phagocyte-derived free radicals stimulated by ingestion of iron rich *S. aureus*: A spin trapping study. *J Infect Dis* 163:419, 1991.
75. Britigan BE, Serody JS, Hayek MB, and **Cohen MS**. Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autooxidation. *J Immunol* 147:4271-7, 1991.
76. Chamulitrat W, **Cohen MS**, and Mason RP. Free radical formation from organic hydroperoxides in isolated human polymorphonuclear neutrophils. *Free Rad Biol Med* 11:439-45, 1991.
77. Hassett DJ, Charniga LM, Bean K, and **Cohen MS**. Antioxidant defense mechanisms in *Pseudomonas aeruginosa*: Resistance to the redox-active antibiotic pyocyanin and demonstration of a manganese cofactor superoxide dismutase. *Infect Immun* 60:328-36, 1992.
78. Ramos CL, Pou S, Britigan BE, **Cohen MS**, and Rosen GM. Spin trapping evidence for myeloperoxidase-dependent hydroxyl radical formation by human neutrophils and monocytes. *J Biol Chem* 267:8307-8312, 1992.
79. Zheng H-Y, Hassett DJ, Bean K, and **Cohen MS**. Regulation of catalase in *N. gonorrhoeae*: effects of oxidant stress and exposure to human neutrophils. *J Clin Invest* 90:1000-6, 1992.
80. **Cohen MS**, Mao J, Rasmussen GT, Serody JS, Britigan BE. Interaction of lactoferrin and Lipopolysaccharide (LPS): Effects of the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. *J Infect Dis* 166:1375-8, 1992.
81. Zheng H-Y, Alcorn TM, **Cohen MS**. Effects of H₂O₂-producing lactobacilli on *Neisseria gonorrhoeae* growth and catalase activity. *J Clin Invest* 90:1000-6, 1992.

82. Serody JS, Mill MR, Detterbeck FC, Harris DT, **Cohen MS**. Blastomycosis in transplant recipients: Report of a case and review. *Clin Infect Dis* 16:54-8, 1993.
83. Gunther MR, Mao J, **Cohen MS**. Oxidant-scavenging activities of ampicillin and sulbactam and their effects on neutrophil functions. *Antimicrob Agents Chemother*, 37:950-6, 1993.
84. Pou S, Gunther MR, Pou WS, Cao GL, Bator JM, **Cohen MS**, Burch RM, Rosen GM. Effect of NPC 15669, an inhibitor of neutrophil recruitment and neutrophil-mediated inflammation, on neutrophil function in vitro. *Biochem Pharmacol* 45:2123-7, 1993.
85. Hassett DJ, Woodruff WA, Wozniak DJ, **Cohen MS**, Ohman DE. Cloning and characterization of *Pseudomonas aeruginosa sodB* encoding iron-cofactored superoxide dismutase. *J Bacteriol* 175:7658-7665, 1993.
86. **Cohen MS**. Molecular events in the activation of human neutrophils for microbial killing. *Clin Infect Dis*. 18(suppl 2):170-179, 1994.
87. Rosen GM, Pou S, Britigan BE, **Cohen MS**. Oxygen radicals in biological systems part C. *Methods in Enzymology* 233:105-111, 1994.
88. Eron JJ, Burkle W, **Cohen MS**. Managing pneumonia: Impact of new macrolide antibiotics. *Hospital Formulary* 29:122-136, 1994.
89. **Cohen MS**, Cannon JG, Jerse AE, Charniga L, Isbey SF, Wicker L. Human experimentation with *Neisseria gonorrhoeae*: Rationale, methods and implications for the biology of infection and vaccine development. *J Infect Dis* 169:532-537, 1994.
90. Wright C, Jerse AE, **Cohen MS**, Cannon JG, Seifert HS. Different DNA sequences are detected when complex mixtures of variable gene sequences are amplified by PCR and directly sequenced. *J Clin Microbiol* 32(2):464-468, 1994.
91. Pou S, Ramos CL, Gladwell T, Renks E, Centra M, Young D, **Cohen MS**, Rosen GM. A kinetic approach to the selection of a sensitive spin trapping system for the detection of hydroxyl radical. *Anal Biochem* 217:76-83, 1994.
92. Jerse AE, **Cohen MS**, Drown PM, Whicker LG, Isbey SF, Seifert HS, Cannon JG. Multiple gonococcal opacity proteins occurs during experimental urethral infection in the male. *J Exp Med* 179:911-920, 1994.
93. Alcorn TM, Zheng H-Y, Hassett DJ, **Cohen MS**. Variation in hydrogen peroxide sensitivity between different strains of *Neisseria gonorrhoeae* is independent of catalase activity. *Infect Immun* 62(5):2138-2140, 1994.
94. Seifert HS, Wright CA, Jerse AE, **Cohen MS**, Cannon JG. Multiple gonococcal pilin antigenic variants are produced during experimental human infections. *J Clin Invest* 93:2744-2749, 1994.
95. Vernazza PL, Eron JJ, **Cohen MS**, van der Horst CM, Troiani L, Fiscus SA. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. *AIDS* 8:1325-1329, 1994.
96. Lule G, Behets FM-T, Hoffman IF, Dalabetta G, Hamilton HA, Moeng S, Liomba G, **Cohen MS**. STD/HIV control in Malawi and the search for affordable and effective urethritis therapy: A first field evaluation. *Genitourin Med* 70(6):384-388, 1994.
97. Woodman RC, Newburger PE, Anklesaria P, Erickson RW, Rae J, **Cohen MS**, Curnutte JT. A new x-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. *Blood* 85:231-241, 1995.
98. Behets F M-T, Liomba G, Lule G, Dallabetta G, Hoffman IF, Hamilton HA, Moeng S, **Cohen MS**. Sexually transmitted diseases/human immunodeficiency virus control in Malawi: A field study of genital ulcer disease. *J Infect Dis* 171(2):451-455, 1995.
99. Gunther MR, Hanna PM, Mason RP, **Cohen MS**. Hydroxyl radical formation from cuprous ion and hydrogen peroxide: A spin trapping study. *Arch Biochem Biophys* 316:515-522, 1995.
100. Stamm WE, Hicks CB, Martin DH, Leone P, Hook EW, Cooper R H, **Cohen MS**, et al. Azithromycin for empiric treatment of nongonococcal urethritis: a randomized, double-blind study. *JAMA* 274:545-549, 1995.

101. Haizlip J, Isbey SF, Hamilton H, Jerse AE, Leone Pa, Davis RH, **Cohen MS**. Time required for elimination of *N. gonorrhoeae* from the urogenital tract after symptomatic urethritis: Comparison of oral and intramuscular therapy. *Sex Transm Dis* 22:145-148, 1995.
102. Jethwa HS, Schmitz JL, Dallabetta G, Behets F, Hoffman I, Hamilton H, **Cohen MS**, Folds JD. Comparison of molecular and microscopic techniques for detection of *Treponema pallidum* in genital ulcers. *J Clin Microbiol* 33:180-183, 1995.
103. Behets FM-T, Desormeaux J, Joseph D, Adrien M, Coicou G, Dallabetta G, Hamilton HA, Moeng S, Davis H, **Cohen MS**, Boulos R. Control of sexually transmitted diseases in Haiti: Results and implications of a baseline study among pregnant women living in Cité Soleil shantytowns. *J Infect Dis* 172:764-71, 1995.
104. **Cohen MS**. HIV and sexually transmitted diseases: The physician's role in prevention. *Postgrad Med J* 98:52-64, 1995.
105. Behets F M-T, Williams Y, Brathwaite A, Hylton-Kong T, Hoffman IF, Dallabetta G, Ward E, **Cohen MS**, Figueroa JP. Management of vaginal discharge in women treated at a Jamaican sexually transmitted disease clinic: Use of diagnostic algorithms versus laboratory testing. *Clin Infect Dis* 21:1450-1455, 1995.
106. **Cohen MS**, Henderson GE, Hamilton H, Aiello P, Zheng H, Brandt A. Eradication of syphilis in China--Lessons for the 20th century? *J Infect Dis*. 174(Suppl.2) S223-230, 1996.
107. Dyer J, Gilliam B, Eron JJ, **Cohen MS**, Fiscus S. Quantitation of human immunodeficiency virus type I RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. *J Virol Methods* 60:161-170, 1996.
108. Desormeaux J, Behets F, Adrien M, Coicou G, Dallabetta G, **Cohen MS**, Boulos R. Introduction of Partner Referral and Treatment for Control of Sexually Transmitted Diseases in a Poor Hatian Community. *Int J STD & AIDS* 7: 502-506, 1996.
109. Eron JJ, Gilliam B, Fiscus S, Dyer J, **Cohen MS**. HIV-1 shedding and chlamydial urethritis (letter). *JAMA* 275: 36, 1996.
110. Dyer J, Gilliam B, Eron JJ, **Cohen MS**, Fiscus S, and Vernazza P. Shedding of HIV in semen during primary HIV infection. *AIDS* 11(4):543-545, 1997.
111. Gilliam BL, Dyer JR, Fiscus SA, Marcus C, Zhou S, Wathen L, Freimuth WW, **Cohen MS**, Eron JJ. Effects of reverse transcriptase inhibitor therapy on HIV-1 viral burden in semen. *J AIDS* 15:54-60, 1997.
112. Royce, AR, Seña, A, Cates, W and **Cohen MS**. Sexual transmission of HIV. *N Engl J Med* 336(15): 1072-1078, 1997.
113. Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Franc AC, Fiscus SA, **Cohen MS** and Eron, JJ. Effect of antiviral treatment on shedding of HIV-1 in semen. *AIDS* 11:1249-1254, 1997.
114. Cates W, Chesney M, and **Cohen MS**. Primary HIV disease: A public health emergency. *Am. J Public Health* 87(12):1928-1930, 1997.
115. Vernazza PL, Gilliam BL, Dyer J, Fiscus SA, Eron JJ, Frank AC, and **Cohen MS**. Quantification of HIV in semen: Correlation with antiviral treatment and immune status. *AIDS* 11:987-993, 1997.
116. Daly CC, Hoffman I, Hobbs M, Maida M, Zimba D, Davis R, Mughogho G, and **Cohen MS**. Development of an antimicrobial susceptibility surveillance system for *Neisseria gonorrhoeae* in Malawi: Comparison of methods. *J Clin Microbiology* 35:2985-2988, 1997.
117. **Cohen MS**, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Zimba D, Vernazza PL, Costello-Daly C, Maida M, Fiscus SA, and Eron JJ. Reduction of Concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. *Lancet* 349:1868-1873, 1997.
118. Isbey SF, Alcorn TM, Davis RH, Haizlip J, Leone PA, **Cohen MS**. Characterisation of *Neisseria gonorrhoeae* in semen during urethral infection in men. *Genitourin Med* 73:378-382, 1997.
119. Schmitz JL, Jenkins PR, McKee KT, Hoffman IF and **Cohen MS**. Comparison of LCR and EIA for detection of *C. trachomatis* in the urine of men with urethritis. *J Clin Microbiology* 35(11):2985-8, 1997.

120. Behets F, Ranaivo A, Andrimiadana J, Andriamahefazafy B, May J, Andriamahenina N, **Cohen MS**, Rasamindrakotroka A. High treponomal seroprevalence among adult hospitalized patients in Tuléar, Madagascar. *Venerology* 10:84-87, 1997.
121. Dyer JR, Eron JJ, Hoffman IF, Kazembe P, Vernazza PL, Nkata E, Costello-Daly C, Fiscus SA, and **Cohen MS**. Association of CD4 depletion and seminal plasma HIV-1 RNA concentrations with genital ulcer disease in HIV-1 infected men in Malawi. *J Infect Dis* 177:224-7, 1998.
122. Dyer JR, Vernazza PL, Gilliam B, Zimba D, Hoffman IF, Royce RR, Fiscus SA, Kazembe P, **Cohen MS** and Eron JJ. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. *J Infect Dis* 177:1742-1746, 1998.
123. **Cohen MS**, Hoffman I. Sexually transmitted diseases enhance transmission of HIV: No longer a hypothesis. *Lancet* 351 (suppl. III): 5-7, 1998.
124. Fiscus SA, Vernazza PL, Gilliam B, Dyer J, Eron JJ, **Cohen MS**. Factors associated with changes in HIV shedding in semen. *AIDS Research and Human Retroviruses* 14 (suppl. 1): S27-S31, 1998.
125. Cornelissen CN, Kelley M, Hobbs MM, Anderson JE, Cannon JG, **Cohen MS**, Sparling PF. The transferrin receptor expressed by gonococcal strain FA1090 is required for experimental infection of human male volunteers. *Mol Microbiol* 27(3):611-616, 1998.
126. Green M, Hoffman IF, Brathwaite A, Wedderburn M, Figueroa P, Behets F, Dallabetta G, Hoyo C, **Cohen MS**. Improving sexually transmitted disease management in the private sector: the Jamaica experience. *AIDS* 12(suppl 2):S67-S72, 1998.
127. Behets F, Génécé E, Narcisse M, Dallabetta G, **Cohen MS**. Approaches to control sexually transmitted diseases Haiti from 1992 through 1995. *WHO Bulletin* 74:s123-S127, 1998.
128. Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, **Cohen MS**. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission. *AIDS* 12(15):F181-F189, 1998.
129. Johannsen DB, Johnston DM, Koymen HO, **Cohen MS**, Cannon JG. A *Neisseria gonorrhoeae* IgA1 protease mutant is infectious in the human challenge model of urethral infection. *Infect. Immun.* (in press), 1998.
130. Green M, Hoffman IF, Brathwaite A, Wedderburn M, Figueroa JP, Behets F, Dallabetta G, Hoyo C, **Cohen MS**. Improving STD management in the private sector: the Jamaican experiment. *AIDS* 12:S67-S72, 1998.
131. Dallabetta G, Behets F, Lule G, Hoffman I, Hamilton H, Wangel AM, Moeng S, **Cohen MS**, Liomba G. Specificity of dysuria and discharge complaints and presence of urethritis in male patients attending an STD clinic in Malawi. *Sex Transm Infect* 74(suppl 1):S34-S37, 1998.
132. Fox KK, Thomas JC, Weiner DH, Davis RH, Sparling PF, **Cohen MS**. Longitudinal evaluation of serovar-specific immunity to *Neisseria gonorrhoeae*. *Am J Epidemiol* 149(4):353-358, 1998.
133. **Cohen MS**, Cannon JG. Human experimentation with *Neisseria gonorrhoeae*: progress and goals. *J.Infect. Dis.* 179 (suppl 2):S375-9, 1999.
134. Pierce RL, Thomas JC, Sparling PF, Fisher W, Davis RH, Alcorn T. **Cohen MS**. An epidemiological evaluation of the use of microbiological tools for identifying gonorrhoea infection networks. *International Journal of STD & AIDS.* 10(5):316-23, 1999.
135. Hobbs MM, Kazembe P, Reed AW, Miller WC, Nkata E, Daly CC, Chakraborty H, **Cohen MS**, Hoffman IF. *Trichomonas vaginalis* as a cause of urethritis in Malawian men. *Sex Transm Dis* 26(7):381-387, 1999.
136. Hoffman IF, Jere CS, Taylor TE, Munthali P, Dyer JR, Wirima JJ, Rogerson SJ, Kumwenda N, Eron JJ, Fiscus SA, Chakraborty H, Taha TE, **Cohen MS**, Molyneux ME. The effect of *Plasmodium falciparum* malaria on HIV-1 RNA blood plasma concentration. *AIDS* 13:487-494, 1999.
137. Ping LH, Nelson JAE, Hoffman IF, Schock J, Lamers SL, Goodman M, Vernazza P, Kazembe P, Maida M, Zimba D, Goodenow MM, Eron JJ, Fiscus SA, **Cohen MS**, Swanstrom R. Characterization of V3 sequence heterogeneity in subtype C HIV-1 isolates from Malawi: underrepresentation of X4 variants. *J Virol* 73(8):6271-6281, 1999.

138. Pereira AS, Kashuba ADM, Fiscus SA, Hall JE, Tidwell RR, Troiani L, Dunn JA, Eron JJ, **Cohen MS**. Antiretroviral therapy and HIV-1 in semen: relationship between drug concentration and viral burden. *J Infect Dis* 180 (6):2039-43, 1999.
139. Behets F, Andriamiadana J, Randrianasolo D, Randriamanga R, Rasamilalao D, Chen C-Y, Weiss J, Morse S, Dallabetta G, **Cohen MS**. Chancroid, primary syphilis, genital herpes, and lymphogranuloma venereum in Antananarivo, Madagascar. *J Infect Dis* 180(4):1382-2, 1999.
140. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, Boggian K, **Cohen MS**, Fiscus SA, Eron JJ, and the Swiss HIV Cohort Study. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. *AIDS* 14(2):117-21, 2000.
141. Shepard RN, Schock J, Robertson K, Shugars DC, Dyer J, Vernazza P, Hall C, **Cohen MS**, Fiscus SA. Quantitation of HIV-1 RNA in different biological compartments. *J Clin Micro* 38(4):1414-8, 2000.
142. Pereira AS, Kenney KB, **Cohen MS**, Hall JE, Eron JJ, Tidwell RR, Dunn JA. Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry. *J Chromatog*, 742:173-183, 2000.
143. **Cohen MS**, Shugars DC, Fiscus SA. Limits on oral transmission of HIV-1, *Lancet* 356(9226):272, 2000.
144. Ping LH, **Cohen MS**, Hoffman IF, Vernazza P, Seillier-Moiseiwitsch F, Chakraborty H, Kazembe P, Zimba D, Maida M, Fiscus SA, Eron JJ, Swanstrom R, Nelson J.A.E. Effects of Genital Tract Inflammation on HIV-1 V3 Populations in Blood and Semen, *J Virology* 74(19):8946-52, 2000.
145. Maida MJ, Costello Daly C, Hoffman I, **Cohen MS**, Kumwenda M, Vernazza PL. Prevalence of hepatitis C infection in Malawi and lack of association with sexually transmitted diseases. *European Journal of Epidemiology* 16:1183-1184, 2000.
146. Kelley M, Weber DJ, Gilligan P, **Cohen MS**. Breakthrough pneumococcal bacteremia in patients on azithromycin/clarithromycin therapy. *Clin Infect Dis* 31:1008-11, 2000.
147. Jordan HL, Pereira AS, **Cohen MS**, Kashuba ADM. Domestic Cats as Models for Predicting Human Nucleoside Analogue Pharmacokinetics in Blood and Seminal Plasma. *Antimicrobial Agents and Chemotherapy* 45:2173-2176, 2001.
148. Joiner KA, Dismukes WE, Britigan BE, **Cohen MS**, Johnson WD, Karchmer AW, Mandell GL, Stamm WE. Adequacy of fellowship training: Results of a survey of recently graduated fellows. *Clin Infect Dis* 32(2):255-62, 2001.
149. Robbins WA, Witt KL, Haseman JK, Dunson DB, Troiani L, **Cohen MS**, Hamilton CD, Perreault SD, Bishop JB and the RTP Germ Cell Working Group. Effects of antiretroviral therapy on genetic and morphological endpoints in lymphocytes and sperm of people with HIV infection. *J Infect Dis* 184(2):127-35, 2001.
150. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, Patterson BK, Coombs RW, Krieger JN, **Cohen MS**. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. *AIDS* 15:621-627, 2001.
151. Behets F, Miller WC, **Cohen MS**. Syndromic treatment of gonococcal and chlamydial infection in women seeking primary care for genital discharge syndrome: decision-making. *Bulletin of the World Health Organization* 79 (11): 1070-1075, 2001.
152. Behets F, Andriamiadana J, Rassamilalao D, Ratsimbazafy N, Randrianasolo D, Dallabetta G, **Cohen MS**. Sexually transmitted infections and associated socio-demographic and behavioral factors in women seeking primary care suggest Madagascar's vulnerability to rapid HIV spread. *Tropical Medicine and International Health* 6:202-211, 2001.
153. Hamrick TS, Dempsey JAF, **Cohen MS**, Cannon JG. Antigenic variation of gonococcal pilin expression in vivo: analysis of the strain FA1090 pilin repertoire and identification of the pilS gene copies recombining with pilE during experimental human infection. *Microbiology* 147:839-849, 2001.
154. Robbins WA, Witt KL, Haseman JK, Dunson DB, Troiani L, **Cohen MS**, Hamilton CD, Perreault SD, Libbus B, Beyler SA, Raburn DJ, Tedder ST, Shelby MD, Bishop JB. Antiretroviral therapy

- effects on genetic and morphologic end points in lymphocytes and sperm of men with human immunodeficiency virus infection. *J Infect Dis* 184:127-35, 2001.
155. Pereira AS, Kenney KB, **Cohen MS**, Eron JJ, Tidwell RR, Dunn JA. Determination of amprenavir concentrations in human seminal plasma using high performance liquid chromatography and tandem mass spectrometry. *J Chromatog.* 766:307-317, 2002.
 156. Behets F, Andriamiadana J, Randrianasolo D, Rasamilalao D, Ratsimbazafy N, Dallabetta G, **Cohen MS**. Laboratory Diagnosis of Sexually Transmitted Infections in Women with Genital Discharge in Madagascar: Implications for Primary Care. *Int J STD & AIDS*: 13: 606-611, 2002.
 157. Kaydos SC, Swygard H, Wise SL, Seña AC, Leone PA, Miller WC, **Cohen MS**, Hobbs MM. Development and validation of a PCR-based enzyme-linked immunosorbent assay with urine for use in clinical research settings to detect *Trichomonas vaginalis* in women. *J Clin Microbiol* 40:89-95, 2002.
 158. Pereira AS, Kenney KB, **Cohen MS**, Hall JE, Eron JJ, Tidwell RR, Dunn JA. Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma and using high-performance liquid chromatography and tandem mass spectrometry. *J Chromatog* 742:173-183, 2002.
 159. Reddy YS, Gotzkowsky SK, Eron JJ, Kim JY, Fiske WD, Fiscus SA, Petch, L, **Cohen MS**, Kashuba, ADM. Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. *J Infectious Diseases* 186:1339-43, 2002.
 160. Feng, T, Ni, A Yang, G, Galvin, SR, Hoffman, I and **Cohen MS**. Distribution of the CCR5 gene 32-base pair deletion and CCR5 expression in Chinese minorities. *J Acquir Immune Defic Syndr* Feb 1; 32: 121-4, 2002.
 161. Parish WL, Laumann, EO, **Cohen MS**, Pan S. Zheng H, Hoffman I, Wang T, Ng KH. The emergent epidemic of STDs in China: a population-based study of behavioral and demographic correlates and implications for public health policy. *JAMA* 289: 1265-73, 2003.
 162. Price MA, Zimba D, Hoffman IF, Kaydos-Daniels SC, Miller WC, Martinson F, Chilongozi D, Kip E, Msowoya E, Hobbs MM, Kazembe PN, **Cohen MS**. The addition of treatment for trichomoniasis to the syndromic management of urethritis in Malawi: a randomized clinical trial. *Sexual Transmitted Disease* 30: 516-522, 2003.
 163. Kaydos-Daniels SC, Miller WC, Hoffman I, Banda T, Dzinyemba W, Martinson F, **Cohen MS**, Hobbs MM. Validation of a urine-based PCR-ELISA for use in clinical research settings to detect *trichomonas vaginalis* in men. *J Clin Micro* 41(1): 318-23, 2003.
 164. Blocker ME, Krysiak RG, Behets F, **Cohen MS**, Hobbs MM. Quantification of Chlamydia trachomatis elementary bodies in urine by ligase chain reaction. *J Clin Microbiology* 40: 3613-3614, 2003.
 165. Hoffman IF, Martinson FE, Stewart PW, Chilongozi DA, Leu SY, Kazembe PN, Banda T, Dzinyemba W, Joshi P, **Cohen MS**, Fiscus SA. Human immunodeficiency virus type 1 RNA in breast-milk components. *J Infect Dis* 188:1209-12, 2003.
 166. Kaydos-Daniels, SC, Miller, WC, Hoffman, I, Price, MA, **Cohen MS**, Namakwha, David, Gama, S, Phakati, S, Chilongozi, D, Hobbs, MM. The use of specimens from various genitourinary tract site in men to detect *T. vaginalis* infection. *J Infect Disease* 189:1926-1931, 2004.
 167. Pilcher CD, Price MA, Hoffman IF, Galvin SR, Martinson FEA, Kazembe PN, Eron JJ, Miller WC, Fiscus SA, and **Cohen, MS**. Frequent detection of acute primary HIV infection in men in Malawi. *AIDS* 18: 1-8, 2004.
 168. Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu S, Stewart PM, Goh L, and **Cohen MS**. Brief but Efficient: Acute HIV Infection and the Sexual Transmission of HIV *J. Infect. Dis.* 189: 1785-1792, 2004.
 169. Huang Y, Henderson GE, Pan, S and **Cohen, MS**. HIV/AIDS Risk among Brothel based Female Sex Workers in China: Assessing the terms, content and knowledge of sex work. *Sex Transm Dis* 11:695-700, 2004.

170. Henderson GJ, Fiscus SA, Hoffman I, McGrath K, **Cohen MS**, Swanstrom R. HIV-1 Populations in blood and breast milk are similar. *Virology* 330: 295-303, 2004.
171. Min SS, Corbett AH, Rezk N, Cu-Uvin S, **Cohen MS**, and Kashuba ADM. Protease inhibitors and non-nucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1 infected women. *J. AIDS* 37: 1577-1580, 2004.
172. Price MA, Miller WC, Kaydos-Daniels SC, Hoffman IF, Chilongozi D, Martinson FE, Namakwha D, Malanda J and **Cohen MS**. Male trichomoniasis and HIV infection: data from two outpatient clinics in the Lilongwe Central Hospital, Malawi. *J Infect Disease* 190: 1448-55, 2004.
173. Hoyo C, Hoffman I, Moser B, Hobbs MM, Kazembe P, Krysiak RG, and **Cohen, MS**. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. *STD* 32: 231-237, 2005.
174. Tucker JD, Henderson GE, Wang TF, Huang Y, Parish W, Pan S, Chen XS, and **Cohen MS**. Surplus men, sex work, and the spread of HIV in China. *AIDS* 19: 539-547, 2005.
175. Price MA, Hoffman IF, Chilongozi D, Martinson FEA, Tembo T, **Cohen MS**. Collecting the essence of man: Semen collection for HIV transmission studies in sub-Saharan Africa. *Sex Transm Infect.* 205: 185-6, 2005.
176. Pilcher CD, Fiscus SA, Nguyen NQ, Foust E, Wolf E, Williams D, Ashby R, Owen O'Dowd J, McPherson JT, Stalzer B, Hightow L, Miller WC, Eron JJ, **Cohen MS**, and Leone P. Detection of acute HIV infections in the general HIV testing population in North Carolina. *N Engl J Med* 352: 1873-83, 2005.
177. Grant RM, Buchbinder S, Cates W, Clarke E, Coates TJ, **Cohen MS**, Delaney M, Flores G, Giocochea P, Gonzales G, Harrington M, Lama J, MacQueen K, Moore JP, Peterson L, Sanchez J, Thompson M, Wainberg MA. Promote chemoprophylaxis research, don't prevent it. *Science* 309: 2170-71, 2005.
178. Petch LA, Hoffman IF, Jere CS, Kazembe PN, Martinson FE, Chilingozi D, Fiscus SA, **Cohen MS**. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naïve adults in Malawi. *AIDS Res Hum Retroviruses* 21(9):799-805, 2005.
179. Miller WC, Swygard H, Hobbs MM, Ford CA, Handcock MS, Morris M, Schmitz JL, **Cohen MS**, Harris KM, Udry JR. The prevalence of trichomoniasis in young adults in the United States. *Sex Transm Dis* 32:593-8, 2005.
180. Gallo MF, Behets F, Steiner MJ, Hobbs MM, Hatzell T, VanDamme K, Ralimamonjy L, Raharimalala L and **Cohen MS**. Prostate-Specific Antigen to Ascertain Reliability of Self-Reported Coital Exposure to Semen. *Sexually Transmitted Diseases.* 33(8):476-479, 2006.
181. Price MA, Stewart SR, Miller WC, Behets F, Dow WH, Martinson FEA, Chilongozi D, and **Cohen MS**. The cost-effectiveness of treating trichomoniasis to avert HIV transmission in men seeking STI care in Malawi. *JAIDS* 43: 202-9, 2006.
182. Berman S and **Cohen MS**. STD treatment: How can it improve HIV prevention in the South. *STD* 33 50-57, 2006.
183. Hobbs MM, Lapple DM, Lawing LF, Schwebke JR, **Cohen MS**, Schwebke JR, Atashili J, Leone PA, Miller WC, and Seña A. Methods for detection of *Trichomona vaginalis* in the male partners of infected women: implications for control of trichomonas in men. *J. Clin Micro* 44:3994-9, 2006.
184. Seña AC, Miller WC, Hobbs MM, Schwebke JR, Leone PA, Swygard, H, Atashili, **Cohen, MS**. Methods for detection of *Trichomona vaginalis* in the male sexual partners: diagnosis, treatment and prevention. *Clin Infect Dis* 44: 13-22, 2007.
185. Pettifor AE, Hudgens MG, Levandowski BA, Rees HV and **Cohen MS**. Highly efficient HIV transmission to young women in South Africa: New clues to the HIV pandemic *AIDS* 27:861, 2007.
186. Fiscus SA, Pilcher CD, Miller WC, Powers KA, Hoffman IF, Price M, Chilingozi D, Mapanje C, Krysiak R, Gama S, Martinson FEA, **Cohen MS**, and Malawi-University of North Carolina Project Acute HIV Infection Study Team. Rapid real time detection of acute HIV infection in patients in Africa *J Infect Dis* 195: 416-424, 2007.

187. Hosseinipour, MC, Napravnik S, Joaki G, Gama JS, Mbeye N, Banda B, Martinson FEA, Hoffman I, and **Cohen MS**. HIV and parasitic infection and the effect of treatment among adult outpatients in Malawi. *J Infect Dis* 195:1278-85, 2007.
188. Chen ZQ, Zhang GC, Gong XD, Lin C, Gao X, Liang GJ, Yue XL, Chen XC, **Cohen MS**. Syphilis in China: Results of the national surveillance program from the Chinese Center for STD Control, Nanjing, China. *Lancet* 369:132-8, 2007.
189. Pilcher CD, Joaki G, Hoffman IF, Martinson FEA, Mapanje C, Stewart PW, Powers KA, Galvin S, Chilongozi D, Gama S, Price MA, Fiscus SA, and **Cohen MS**. Amplified transmission of HIV-1: Comparison of HIV-1 concentrations in blood and semen in acute and chronic infection. *AIDS* 21: 1723-30, 2007.
190. Powers KA, Miller WC, Pilcher CD, Mapanje C, Martinson FEA, Fiscus SA, Chilongozi D, Namakhwa D, Gama S, Price M, Galvin S, Hoffman I, **Cohen MS** and the Malawi UNC Project Acute HIV Study Team. Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of A risk score algorithm. *AIDS* 21:2237-42, 2007.
191. Dumond J, Yeh R, Patterson KB, Corbett AH, Jung B-H, Rezk NL, Bridges AX, Dempsey EX, **Cohen MS**, and Kashuba ADM. Antiretroviral drug exposure in the female genital: implications for oral pre- and post-exposure prophylaxis. *AIDS* 21: 1899-1907, 2007.
192. **Cohen MS**. Preventing Sexual Transmission of HIV. 2007. *Clin Infect Dis* 45: S287-S292, 2007.
193. **Cohen MS**, Gay C, Kashuba AD, Blower S, and Paxton L. Narrative Review: antiretroviral therapy to prevent the sexual transmission of HIV-1. *Ann Intern Med* 146: 591-601, 2007.
194. Chen XC, Wong SI, Lin C, Tucker J, Zhang GC, Gong XD, Gao X, Liang GJ, Yue XL, Chen XC, and **Cohen MS** for the Guangxi research team. Syphilis in China: results of a national surveillance program. *Lancet* 369: 132-138, 2007.
195. Chen XS, Yin YP, Tucker JD, Gao X, Cheng F, Wang TF, Wang HC, Huang PY, and **Cohen MS**. Detection of acute and established HIV infections in sexually transmitted disease clinics in Guanxi, China: Implications for screening and prevention of HIV infection. *J Infect Dis* 196: 1654-1661, 2007.
196. Wong SP, Yin YP, Gao X, Wei WH, Shi MQ, Huang PY, Wang H, Chen Q, Liu M, Tucker JD, Chen XS, and **Cohen MS**. Risk of syphilis in STI clinic patients: a cross-sectional study of 11,500 cases in Guangxi, China. *Sex Transm Infect.* 83: 351-356, 2007.
197. Dumond JB, Reddy YS, Troiani L, Rodriguez JF, Bridges AS, Fiscus SA, Yuen GJ, **Cohen MS** and Kashuba AD. Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1infected men. *JAIDS* 48: 156-62, 2008.
198. Vourvahis M, Tappouri HL, Patterson KB, Chen YC, Rezk N, Fiscus SA, Kearney BP, Rooney JM, Hui J, **Cohen MS** and Kashuba ADM. The pharmacokinetics and viral activity of tenofovir in the male genital tract. *JAIDS* 47(3):329-33, 2008.
199. Keele BF, Giorgi EE, Salazar-Gomez JF, Decker JM, Salazar MG, Sun C, Grayson T, Wang S, Li H, We X, Jiang C, Gao F, Anderson JA, Ping LH, Swanstrom R, Tomaras G, Blattner WA, Goefert PA, Saag MS, Delwart F, Busch MP, **Cohen MS**, Montefiore DC, Haynes BF, Gaschen B, Athreya GS, Lee HY, Wood N, Seoighe C, Perelson,AS, Bjattacharya T, Korber BT, Hahn BH and Shaw W. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci* 105:7552-7557, 2008.
200. Yin YP, Chen XS, Wang HC, Shi MQ, Zhu BY, Yu YH, Tucker JD, and **Cohen MS**. Detection of acute HIV infections among sexually transmitted disease clinic clients: a practice in Guangxi Zhuang Autonomous Region, China. *Sex Transm Inf*, 84: 350-1, 2008.
201. Pettifor A, Levandowski BA, MacPhail C, Ford C, Miller WC, Stein C, Rees H, and **Cohen MS**. Rethinking the basis for the AIDS pandemic: Comparison of the sexual behaviors of adolescents in South Africa and the United States (AJPH, submitted)
202. **Cohen MS**, Hellmann N, Levy JA, DeCock K, and Lange J. The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. *J Clin Invest* 118:1244-54, 2008.

203. Yin YP, Wong SP, Liu MS, Wei WH, Yu YH, Gao X, Chen Q, Fu ZZ, Cheng F, Chen XS and **Cohen MS**. Syphilis control in China: selective testing of sexually transmitted disease patients-too little, too late? *Int J STD AIDS* 19: 838-42, 2008.
204. **Cohen MS**, Calibu P, Coates T. Prevention of the sexual transmission of the sexual transmission of HIV-1: preparing for success. *J. Int AIDS Soc.* 11:4. 2008.
205. Wang Y, Li B, Zheng J, Sengupta S, Emrick CB, **Cohen MS**, and Henderson G. Factors related to female sex workers willingness to utilize VCT service: A qualitative study in Jinan City, Northern China. *AIDS Behav.* 2008.
206. Powers KA, Poole C, Pettifor AE, and **Cohen MS**. Rethinking the heterosexual transmission of HIV-1: A systematic review and meta-analysis. *Lancet Infect Dis:* 8:553-63, 2008.
207. Pettifore AE, Levandowski BS, Macphail C, Padian NS, **Cohen MS**, Rees HV. Keeping them in school: the importance of education as a protective factor against HIV among South African women. *Int. J Epi.* 32: 1266-73, 2008.
208. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, **Cohen MS**, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. Initial B-cell responses to transmitted human immunodeficiency virus type-1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by anti-gp41 antibodies with ineffective control of viremia. *J. Viro* 82: 12449-63, 2008.
209. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, Salazar-Gonzalez JF, Bhattacharya T, Chu H, Hoffman I, Galvin S, Mapanje C, Kazembe P, Thebus R, Fiscus S, Hide W, **Cohen MS**, Karim SA, Haynes BF, Shaw GM, Hahn BH, Korber BT, Swanstrom R, Williamson C; CAPRISA Acute Infection Study Team; Center for HIV-AIDS Vaccine Immunology Consortium. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. *J Virol.* 83:3556-67, 2008.
210. Yin YP, Wei WH, Wang HC, Zhu BY, Yu YH, Chen XS, Peeling RW, **Cohen MS**. Performance of serological tests for syphilis in sexually transmitted diseases clinics in Guangxi Autonomous Region, China: implications for syphilis surveillance and control. *Sex Health.* 6, 5-9 2009.
211. Gao F, Scarce RM, Alam SM, Hora B, Xia S, Hohm JE, Parks RJ, Ogburn DF, Tomaras GD, Park E, Lomas WE, Maino VC, Fiscus SA, **Cohen MS**, Moody MA, Hahn BH, Korber BT, Liao HX, Haynes BF. Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. *Virology.* 394(1):91-8, 2009.
212. Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, Gurley TC, Allgood S, Haynes BB, Vandergrift NA, Plonk S, Parker DC, **Cohen MS**, Tomaras GD, Goepfert PA, Shaw GM, Schmitz JE, Eron JJ, Shaheen NJ, Hicks CB, Liao HX, Markowitz M, Kelsoe G, Margolis DM, Haynes BF. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. *PLoS Med.* 6(7):e1000107, 2009.
213. Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, **Cohen MS**, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *J Exp Med.* 206:1273-89. 2009.
214. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, Ghanusov VV, Keele BF, Learn GH, Turnbull EL, Salazar MG, Weinhold KJ, Moore S; CHAVI Clinical Core B, Letvin N, Haynes BF, **Cohen MS**, Hraber P, Bhattacharya T, Borrow P, Perelson AS, Hahn BH, Shaw GM, Korber BT, McMichael AJ. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *J Exp Med.* 206:1253-72, 2009.
215. Walley NM, Julg B, Dickson SP, Fellay J, Ge D, Walker BD, Carrington M, **Cohen MS**, de Bakker PI, Goldstein DB, Shianna KV, Haynes BF, Letvin NL, McMichael AJ, Michael NL, Weintrob AC.

- The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. *Cell Host Microbe* 5:408-10; author reply 418-9, 2009.
216. **Cohen MS**, Mastro TD, Cates W Jr. Universal voluntary HIV testing and immediate antiretroviral therapy. *Lancet*. 37:1080-1, 2009.
 217. Yin YP, Wei WH, Wang HC, Zhu BY, Yu YH, Chen XS, Peeling RW, **Cohen MS**. Performance of serological tests for syphilis in sexually transmitted diseases clinics in Guangxi Autonomous Region, China: implications for syphilis surveillance and control. *Sex Health*. 6:5-9, 2009.
 218. **Cohen MS** and Gay CL. Treatment to Prevent Transmission of HIV-1. *Clin Infect Dis*. 15;50 Suppl 3:S85-95, 2010.
 219. Gay CL, Mwapasa V, Murdoch DM, Kwiek JJ, Fiscus SA, Meshnick SR, **Cohen MS**. Acute HIV infection among pregnant women in Malawi. *Diagn Microbiol Infect Dis*.66:356-60, 2010.
 220. Tucker JD, Yang LG, Zhu ZJ, Yang B, Yin YP, **Cohen MS**, Chen XS. Integrated syphilis/HIV screening in China: a qualitative analysis. *BMC Health Serv Res*. 10:58, 2010.
 221. Powers KA, Hoffman IF, Ghani AC, Hosseinipour MC, Pilcher CD, Price MA, Chilongozi DA, Martinson FEA, **Cohen MS**, Miller WC. Sexual partnership patterns in Malawi: implications for HIV/STI transmission. *Sex Transm Dis*. 2011 Jul;38(7):657-66.
 222. Brown LB, Miller WC, Kamanga G, Nyirenda N, Mmodzi P, Pettifor A, Dominik RC, Kaufman JS, Mapanje J, Martinson F, **Cohen MS** and Hoffman IF. HIV partner notification is effective and feasible in sub-Saharan Africa: Opportunities for improved HIV treatment and prevention. *J Acquir Immune Defic Syndr*. 2011 Apr 15;56(5):437-42.
 223. Brown LB, Krysiak R, Kamanga G, Mapanje C, Kanyamula H, Banda B, Mhango C, Hoffman M, Kamwendo D, Hobbs M, Hosseinipour MC, Martinson F, **Cohen MS**, Hoffman IF. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi. *Sex Transm Dis*. 37(3):169-72, 2010.
 224. Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, Kincer L, Tang Y, Hobbs M, Hoffman I, Kazembe P, Jones CD, Borrow P, Fiscus S, **Cohen MS**, Swanstrom R; Center for HIV/AIDS Vaccine Immunology. HIV-1 Populations in Semen Arise through Multiple Mechanisms. *PLoS Pathog*. e1001053, 2011.
 225. Masharsky AE, Dukhovlinova EN, Verevchkin SV, Toussova OV, Skochilov RV, Anderson JA, Hoffman I, **Cohen MS**, Swanstrom R, Kozlov AP. A substantial transmission bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg, Russia. *J Infect Dis*. 1;201(11):1697-702, 2010.
 226. Phiri S, Hoffman IF, Weiss HA, Martinson F, Nyirenda N, Kamwendo D, Fiscus SA, Chen CY, Miller WC, van der Hoeven L, Chilongozi D, **Cohen MS**, Mayaud P. Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi. *Sex Transm Infect*. 86(5):345-52, 2010.
 227. Wang Y, Li B, Pan J, Sengupta S, Emrick CB, **Cohen MS**, Henderson GE. Factors Associated with Utilization of a Free HIV VCT Clinic by Female Sex Workers in Jinan City, Northern China. *AIDS Behav*. 2010 May 11.
 228. Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn GH, Morgan CJ, Schumacher JE, Hraber P, Giorgi EE, Bhattacharya T, Korber BT, Perelson AS, Eron JJ, **Cohen MS**, Hicks CB, Haynes BF, Markowitz M, Keele BF, Hahn BH, Shaw GM. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. *PLoS Pathog*. 6(5):e1000890, 2010.
 229. Mastro TD and **Cohen MS**. Honing the test-and-treat HIV strategy. *Science*. 21;328(5981):976, 2010.
 230. Sun K, Zhou S, Chen RY, **Cohen MS**, Zhang F. Recent key advances in human immunodeficiency virus medicine and implications for China. *AIDS Res Ther*. 7:12, 2010.
 231. Tucker JD, Bu J, Brown LB, Yin YP, Chen XS, **Cohen MS**. Accelerating worldwide syphilis screening through rapid testing: a systematic review. *Lancet Infect Dis*. 10(6):381-6, 2010.

232. Pearlman RV, Tucker JD, Yuan LF, Bu J, Yin YP, Chen XS, **Cohen MS**. Sexually transmitted infections among individuals over fifty years of age in China. *AIDS Patient Care STDS*. 24(6):345-7, 2010.
233. **Cohen MS**, Fidler S. HIV prevention 2010: where are we now and where are we going? *Curr Opin HIV AIDS*. 5(4):265-8, 2010.
234. Tucker JD, Hawkes SJ, Yin YP, Peeling RW, **Cohen MS**, Chen XS. Scaling up syphilis testing in China: implementation beyond the clinic. *Bull World Health Organ*. 88(6):452-7, 2010.
235. Zhou P, Li K, Lu H, Qian Y, Gu X, Gong W, Tucker JD, **Cohen MS**. Azithromycin treatment failure among primary and secondary syphilis patients in Shanghai. *Sex Transm Dis*. 37(11):726-9, 2010.
236. **Cohen MS**, Swygard H. Human immunodeficiency virus infection and partner services: a monumental missed opportunity. *Sex Transm Dis*. 37(8):476-7, 2010.
237. Anderson JA, Ping LH, Dibben O, Jabara CB, Arney L, Kincer L, Tang Y, Hobbs M, Hoffman I, Kazembe P, Jones CD, Borrow P, Fiscus S, **Cohen MS**, Swanstrom R; Center for HIV/AIDS Vaccine Immunology. HIV-1 Populations in Semen Arise through Multiple Mechanisms. *PLoS Pathog*. 19;6(8), 2010.
238. **Cohen MS**, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. *J Infect Dis*. 202 Suppl 2:S270-7, 2010.
239. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, **Cohen MS**, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. *PLoS Comput Biol*. 7;6(10):e1000955, 2010.
240. Pettifor A, Macphail C, Corneli A, Sibeko J, Kamanga G, Rosenberg N, Miller WC, Hoffman I, Rees H, **Cohen MS**; NIAID Center for HIV/AIDS Vaccine Immunology. Continued High Risk Sexual Behavior Following Diagnosis with Acute HIV Infection in South Africa and Malawi: Implications for Prevention. *AIDS Behav*. 2010 Oct 27.
241. Tucker JD, **Cohen MS**. China's syphilis epidemic: epidemiology, proximate determinants of spread, and control responses. *Curr Opin Infect Dis*. 24(1):50-5, 2011.
242. Petrovski S, Fellay J, Shianna KV, Carpenetti N, Kumwenda J, Kamanga G, Kamwendo DD, Letvin NL, McMichael AJ, Haynes BF, **Cohen MS**, Goldstein DB; on behalf of the Center for HIV/AIDS Vaccine Immunology. Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. *AIDS*. 20;25(4):513-518, 2011.
243. Champion S, **Cohen MS**, McMichael AJ, Galvin S, Goonetilleke N. Improved detection of latent *Mycobacterium tuberculosis* infection in HIV-1 seropositive individuals using cultured cellular assays. *Eur J Immunol*. 41(1):255-7, 2011.
244. Corrah TW, Goonetilleke N, Kopycinski J, Deeks SG, **Cohen MS**, Borrow P, McMichael A, Brackenridge S. A reappraisal of the relationship between the hiv-1-protective single nucleotide polymorphism 35kb upstream of the hla-c gene and surface hla-c expression. *J Virol*. 2011 Jan 19.
245. Ritchie AJ, Champion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, Moore S, Liu MK, Brackenridge S, Kuldanek K, Legg K, **Cohen MS**, Delwart EL, Haynes BF, Fidler S, McMichael AJ, Goonetilleke N. Differences in HIV specific T cell responses between HIV seronegative exposed and unexposed individuals. *J Virol*. 2011 Apr;85(7):3507-16.
246. Brown KC, Patterson KB, Malone SA, Shaheen NJ, Prince HM, Dumond JB, Spacek MB, Heidt PE, **Cohen MS**, Kashuba AD. Single and multiple dose pharmacokinetics in saliva, semen and rectal tissue of healthy HIV-negative men. *J Infect Dis*. 2011. 203: 1484-90.
247. **Cohen MS**, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaud H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; the HPTN 052 Study Team. Prevention of HIV infection with early Antiretroviral therapy. *New Eng J Med*. 363: 493-505, 2011.

248. Padian NS, McCoy SI, Karim SS, Hasen N, Kim J, Bartos M, Katabira E, Bertozzi SM, Schwartländer B, **Cohen MS**. HIV Prevention transformed: the new prevention research. *Lancet* 378: 269-78, 2011.
249. Smith K, Powers KA, Kashuba AD, **Cohen MS**. HIV treatment as prevention: the good, the bad and challenges. *Current Opin HIV. AIDS* 6: 315-25, 2011.
250. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, Martinson FE, **Cohen MS**. The role of acute and early HIV infection and implication for transmission prevention strategies in Lilongwe, Malawi: a modeling study. *Lancet* 378: 256-68, 2011.
251. **Cohen MS**, Shaw GM, McMichael AJ, Haynes BF. Acute HIV infection. *New Engl. J Med.* 364:1943-54, 2011.
252. Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, Norris PJ, Kuruc JD, Salazar-Gonzalez JF, Li H, Keele BF, Hicks C, Margolis D, Ferrari G, Haynes B, Swanstrom R, Shaw GM, Hahn BH, Eron JJ, Borrow P, **Cohen MS**. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. *PloS One*, e1967, 2011
253. Patterson KB, Prince HA, Kraft E, Jenkins AJ, Shaheen NJ, Rooney JF, **Cohen MS**, Kashuba AD. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. *Sci Transl Med.* 2011 7;3(112):112re4.
254. Kashuba AD, Patterson KB, Dumond JB, **Cohen MS**. Pre-exposure prophylaxis for HIV-1 prevention: how to predict success. *Lancet.* 2012 Jun 30;379(9835):2409-11.
255. Tucker JD, Yin YP, Wang B, Chen XS, **Cohen MS**. An expanding syphilis epidemic in China: epidemiology, behavioural risk and control strategies with a focus on low-tier sex workers and men who have sex with men. *Sex Transm Infect.* 87: Suppl 2:ii16-ii18, 2011.
256. Brown LB, Miller WC, Kamanga G, Kaufman JS, Pettifor A, Dominik RC, Nyirenda N, Mmodzi P, Mapanje C, Martinson F, **Cohen MS**, Hoffman IF. Predicting partner HIV testing and counseling following a partner notification intervention. *AIDS Behav.* 2011 Nov 27.
257. Brown LB, Miller WC, Kamanga G, Nyirenda N, Mmodzi P, Pettifor A, Dominik RC, Kaufman JS, Mapanje C, Martinson F, **Cohen MS**, Hoffman IF. HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. *J Acquir Immune Defic Syndr.* 15;56(5):437-42, 2011.
258. Mastro TD, **Cohen MS**, Rees H Anti retrovirals for safer conception for HIV-negative women and their HIV-1 infected male partners: how safe and how available. *AIDS* 25(16):2049-51, 2011.
259. Eshleman SH, Hudelson SE, Redd AD, Wang L, Debes R, Chen YQ, Martens CA, Ricklefs SM, Selig EJ, Porcella SF, Munshaw S, Ray SC, Piwowar-Manning E, McCauley M, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, de Bruyn G, Grinsztejn B, Kumarasamy N, Makhema J, Mayer KH, Pilotto J, Santos BR, Quinn TC, **Cohen MS**, Hughes JP. Analysis of genetic linkage of HIV from couples enrolled in the HIV prevention Trials Network 052 Trial. *J Infect Dis.* 15;204(12):1918-26, 2011.
260. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, **Cohen MS**, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Margaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associate with early or chronic infections. *PLoS Pathog.* 2011 Sep;7(9):e1002209.
261. Hurt CB, Eron JJ Jr, **Cohen MS**. Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? *Clin Infect Dis.* 2011 Dec;53(12):1265-70.
262. Stuart GS, Moses A, Corbett A, Phiri G, Kumwenda W, Mkandawire N, Chintedze J, Malunga G, Hosseinipour M, **Cohen MS**, Stanczyk FZ, Kashuba AD. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. *J Acquir Immune Defic Syndr.* 2011 Oct 1;58(2):e40-3.

263. Li HM, Peng RR, Li J, Yin YP, Wang B, **Cohen MS**, Chen XS. HIV incidence among men who have sex with men in China: a meta-analysis of published studies. *PLoS One*. 2011;6(8):e23431. Epub 2011 Aug 26
264. Liu P, Overman RG, Yates NL, Alam SM, Vandergrift N, Chen Y, Graw F, Freel SA, Kappes JC, Ochsenbauer C, Montefiori DC, Gao F, Perelson AS, **Cohen MS**, Haynes BF, Tomaras GD. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. *J Virol*. 2011 Nov;85(21):11196-207.
265. Yates NL, Lucas JT, Nolen TL, Vandergrift NA, Soderberg KA, Seaton KE, Denny TN, Haynes BF, **Cohen MS**, Tomaras GD. Multiple IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. *AIDS*. 2011 Nov 13;25(17):2089-97
266. Stuart GS, Moses A, Corbett A, Phiri G, Kumwenda W, Mkandawire N, Chintedze J, Malunga G, Hosseinipour M, **Cohen MS**, Stanczyk FZ, Kashuba AD. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. *J Acquir Immune Defic Syndr*. 2011 Oct 1;58(2):e40-3.
267. **Cohen MS**, Eron J, Soderberg K Jr, McMichael A. High clade C HIV-1 viremia: How did we get here and where are we going. *AIDS*. 2011 Jul 31;25(12):1543-5.
268. Hobbs MM, Sparling PF, **Cohen MS**, Shafer WM, Deal CD, Jerse AE. Experimental gonococcal infection in male volunteer: Cumulative experience with *Neisseria gonorrhoeae* strains FAA1090 and MS11mkC. *Front Microbiol*. 2011;2:123. Epub 2011 May 31.
269. Pettifor A, MacPhail C, Corneli A, Sibeko J, Kamanga G, Rosenberg N, Miller WC, Hoffman I, Rees H, **Cohen MS**; NIAID Center for HIV/AIDS Vaccine Immunology. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. *AIDS Behav*. 2011 Aug;15(6):1243-50.
270. Pettifor, AE, Levandowski, BA, Macphail, C Miller, WC, Tabor, J, Ford, C, Stein, CR, Rees, H, **Cohen MS**. A tale of two countries: rethinking sexual risk for HIV among young people in South Africa and the United States. *Adolesc. Health*. 2011; 3: 237-243.
271. Tucker JD, Yang LG, Yang B, Young D, Henderson GE, Huang SJ, Lu HK, Chen XS, **Cohen MS**. Prior HIV Testing Among STD Patients in Guangdong Province, China: Opportunities for Expanding Detection of Sexually Transmitted HIV Infection. *Sex Transm Dis*. 2012 Mar;39(3):182-187.
272. **Cohen MS**, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. *Curr Opin HIV AIDS*. 2012 Mar;7(2):99-105.
273. Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. Rosenberg NE, Kamanga G, Phiri S, Nsona D, Pettifor A, Rutstein SE, Kamwendo D, Hoffman IF, Keating M, Brown LB, Ndalama B, Fiscus SA, Congdon S, **Cohen MS**, Miller WC. *J Infect Dis*. 2012 528-34. Epub 2011 Dec 29.
274. Kashuba AD, Patterson KB, Dumond JB, **Cohen MS**. Pre-exposure prophylaxis for HIV prevention: how to predict success. *Lancet*;379(9835):2409-11. Epub 2011 Dec 6, 2012.
275. **Cohen, MS**, Holmes, C, Padian, N, Hirschall, G, Ying RL and Goosby, E. Treatment as prevention for the global Aids response from discovery to policy. *Health Affairs*, 2012. 31:1439-49.
276. **Cohen MS**, Holmes C, Padian N, Wolf M, Hirschall G, Lo YR, Goosby E. HIV treatment as prevention: how scientific discovery occurred and translated rapidly into policy for the global response. *Health Aff (Millwood)*. 2012 Jul;31(7):1439-49.
277. Smith, K, Muessig, KE, Powers, KS Miller, WC and **Cohen MS**. ART and population level prevention of HIV: Ecology, observation and interpretation (PLOS Med Published 10 Jul 2012).
278. **Cohen MS**, Dye, C, Fraser, C, Miller, WC, Powers KA, Williams, B G. Using antiretroviral therapy to control heterosexual transmission of HIV: what is the role of early transmission. *PLOS MED* Published 10 Jul 2012.
279. **Cohen MS**, McCauley M, Sugarman J. Establishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odyssey. *Clin Trials*. 2012;9 :340-7.

280. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, **Cohen MS**, Coffin JM, Bosch RJ, Gay CL, Eron JJ, Margolis DM, Perelson AS. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl Acad Sci U S A*. 2012 Jun 12;109:9523-8.
281. Lynch RM, Tran L, Louder MK, Schmidt SD, **Cohen MS**, CHAVI 001 Clinical TeamMembers, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. The development of CD4 binding site antibodies during HIV-1 infection. *J Virol*. 2012 Jul;86(14):7588-95.
282. Freel SA, Picking RA, Ferrari G, Ding H, Ochsenbauer C, Kappes JC, Kirchherr JL, Soderberg KA, Weinhold KJ, Cunningham CK, Denny TN, Crump JA, **Cohen MS**, McMichael AJ, Haynes BF, Tomaras GD. Initial HIV-1 Antigen-Specific CD8+ T Cells in Acute HIV-1 Infection Inhibit Transmitted/Founder Virus Replication. *J Virol*. 2012 Jun;86(12):6835-46.
283. **Cohen MS**, Muessig KE, Smith MK, Powers K, Kashuba AD. Antiviral agents and HIV prevention: controversies, conflicts and consensus. *AIDS*. 2012 Aug 24;26(13):1585-98.
284. Tucker JD, Walensky RP, Yang LG, Yang B, Bangsberg DR, Chen XS, **Cohen MS**. Expanding provider-initiated HIV testing at STI clinics in China. *AIDS Care*. 2012;24(10):1316-9. Epub 2012 Apr 18.
285. Brown KC, Patterson KB, Jennings SH, Malone SA, Shaheen NJ, Asher Prince HM, Spacek M, **Cohen MS**, Kashuba A. Single and Multiple Dose Pharmacokinetics of Darunavir plus Ritonavir and Etravirine in Semen and Rectal Tissue of HIV-Negative Men. *J Acquir Immune Defic Syndr*. 2012 May 18.
286. Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN, Grulich AE, Phillips AN, **Cohen MS**. Does ART prevent HIV transmission among MSM? *AIDS*. 2012 Nov 28;26(18):2267-73.
287. Wang AL, Peng RR, Tucker JD, **Cohen MS**, Chen XS. Partner notification uptake for sexually transmitted infections in China: a systematic literature review. *Sex Transm Infect*. 2012 Mar 18.
288. Dumond JB, Nicol MR, Kendrick RN, Garonzik SM, Patterson KB, **Cohen MS**, Forrest A, Kashuba AD. Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. *Clin Pharmacokinet*. 2012 Dec;51(12):809-22.
289. Hurt CB, Beagle S, Leone PA, Sugarbaker A, Pike E, Kuruc J, Foust EM, Eron JJ Jr, **Cohen MS**, Hightow-Weidman LB. Investigating a sexual network of black men who have sex with men: implications for transmission and prevention of HIV infection in the United States. *J Acquir Immune Defic Syndr*. 2012 Dec 1;61(4):515-21.
290. **Cohen MS**, Muessig KE, Smith MK, Powers KA, Kashuba AD. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. *AIDS*. 2012 Aug 24;26(13):1585-98. Review.
291. Wang AL, Peng RR, Tucker JD, **Cohen MS**, Chen XS. Partner notification uptake for sexually transmitted infections in China: a systematic literature review. *Sex Transm Infect*. 2012 Aug;88(5):386-93.
292. Smith MK, Powers KA, Muessig KE, Miller WC, **Cohen MS**. HIV treatment as prevention: the utility and limitations of ecological observation. *PLoS Med*. 2012;9(7):e1001260. Epub 2012 Jul 10. Review.
293. **Cohen MS**, Dye C, Fraser C, Miller WC, Powers KA, Williams BG. HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? *PLoS Med*. 2012;9(7):e1001232. Epub 2012 Jul 10.
294. Chen YQ, Masse B, Wang L, Ou SS, Li X, Donnell D, McCauley M, Gamble T, Ribauldo HJ, **Cohen MS**, Fleming TR. Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. *Contemp Clin Trials*. 2012 Nov;33(6):1280-6.
295. **Cohen MS**, Baden LR. Preexposure prophylaxis for HIV--where do we go from here? *N Engl J Med*. 2012 Aug 2;367(5):459-61.

296. Liu MK, Hawkins N, Ritchie AJ, Ganusov VV, Whale V, Brackenridge S, Li H, Pavlicek JW, Cai F, Rose-Abrahams M, Treurnicht F, Hraber P, Riou C, Gray C, Ferrari G, Tanner R, Ping LH, Anderson JA, Swanstrom R; CHAVI Core B, **Cohen MS**, Karim SS, Haynes B, Borrow P, Perelson AS, Shaw GM, Hahn BH, Williamson C, Korber BT, Gao F, Self S, McMichael A, Goonetilleke N. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. *J Clin Invest*. 2013 Jan 2;123(1):380-93.
297. Wang XB, Tucker JD, Yang L, Zheng H, Zhang F, **Cohen MS**, Yang B, Cai W. Unsafe Sex and STI Prevalence Among HIV-Infected Adults in Guangzhou, China: Opportunities to Deamplify Sexual HIV Transmission. *AIDS Behav*. 2013 Mar;17(3):1137-43.
298. Zhu H, Napravnik S, Eron JJ, Cole SR, Ma Y, Wohl DA, Dou Z, Zhang Y, Liu Z, Zhao D, Yu L, Liu X, **Cohen MS**, Zhang F. Decreasing Excess Mortality of HIV-infected Patients Initiating Antiretroviral Therapy: Comparison with Mortality in General Population in China, 2003 - 2009. *J Acquir Immune Defic Syndr*. 2013 Apr 8.
299. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, Fire AZ, Roskin KM, Schramm CA, Zhang Z, Zhu J, Shapiro L; NISC Comparative Sequencing Program, Mullikin JC, Gnanakaran S, Hraber P, Wiehe K, Kelsoe G, Yang G, Xia SM, Montefiori DC, Parks R, Lloyd KE, Scarce RM, Soderberg KA, **Cohen MS**, Kamanga G, Louder MK, Tran LM, Chen Y, Cai F, Chen S, Moquin S, Du X, Joyce MG, Srivatsan S, Zhang B, Zheng A, Shaw GM, Hahn BH, Kepler TB, Korber BT, Kwong PD, Mascola JR, Haynes BF. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature*. 2013 Apr 25;496(7446):469-76.
300. Miller WC, Powers KA, Smith MK, **Cohen MS**. Community viral load as a measure for assessment of HIV treatment as prevention. *Lancet Infect Dis*. 2013 May;13(5):459-64.
301. Medley A, Baggaley R, Bachanas P, **Cohen MS**, Shaffer N, Lo YR. Maximizing the impact of HIV prevention efforts: Interventions for couples. *AIDS Care*. 2013 May.
302. McNairy ML, **Cohen MS**, El-Sadr WM. Antiretroviral therapy for prevention is a combination strategy. *Curr HIV/AIDS Rep*. 2013 Jun;10(2):152-8.
303. Patterson KB, Prince HA, Stevens T, Shaheen NJ, Dellon ES, Madanick RD, Jennings S, **Cohen MS**, Kashuba AD. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. *AIDS*. 2013 Jun 1;27(9):1413-9.
304. Yates NL, Stacey AR, Nolen TL, Vandergrift NA, Moody MA, Montefiori DC, Weinhold KJ, Blattner WA, Borrow P, Shattock R, **Cohen MS**, Haynes BF, Tomaras GD. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. *Mucosal Immunol*. 2013 Jul;6(4):692-703.
305. Ping LH, Joseph SB, Anderson JA, Abrahams MR, Salazar-Gonzalez JF, Kincer LP, Treurnicht FK, Arney L, Ojeda S, Zhang M, Keys J, Potter EL, Chu H, Moore P, Salazar MG, Iyer S, Jabara C, Kirchherr J, Mapanje C, Ngandu N, Seoighe C, Hoffman I, Gao F, Tang Y, Labranche C, Lee B, Saville A, Vermeulen M, Fiscus S, Morris L, Karim SA, Haynes BF, Shaw GM, Korber BT, Hahn BH, **Cohen MS**, Montefiori D, Williamson C, Swanstrom R; CAPRISA Acute Infection Study and the Center for HIV-AIDS Vaccine Immunology Consortium. Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. *J Virol*. 2013 Jul;87(13):7218-33.
306. El-Sadr WM, Serwadda DM, Sista N, **Cohen MS**. HIV prevention: great achievements, more challenges ahead. *J Acquir Immune Defic Syndr*. 2013 Jul;63 Suppl 2:S115-6.
307. Smith MK, Rutstein SE, Powers KA, Fidler S, Miller WC, Eron JJ Jr, **Cohen MS**. The detection and management of early HIV infection: a clinical and public health emergency. *J Acquir Immune Defic Syndr*. 2013 Jul;63 Suppl 2:S187-99.
308. Thompson CG, **Cohen MS**, Kashuba AD. Antiretroviral pharmacology in mucosal tissues. *J Acquir Immune Defic Syndr*. 2013 Jul;63 Suppl 2:S240-7.
309. Greener BN, Patterson KB, Prince HM, Sykes CS, Adams JL, Dumond JB, Shaheen NJ, Madanick RD, Dellon ES, **Cohen MS**, Kashuba AD. Dolutegravir pharmacokinetics in the genital tract and

- colorectum of HIV-negative men after single and multiple dosing. *J Acquir Immune Defic Syndr*. 2013 Sep 1;64(1):39-44.
310. Ping LH, Jabara CB, Rodrigo AG, Hudelson SE, Piwowar-Manning E, Wang L, Eshleman SH, **Cohen MS**, Swanstrom R. HIV-1 Transmission during Early Antiretroviral Therapy: Evaluation of Two HIV-1 Transmission Events in the HPTN 052 Prevention Study. *PLoS One*. 2013 Sep 24;8(9):e71557.
 311. Schwartz SR, Pettifor A, Stuart GS, **Cohen MS**. Hormonal contraception and HIV: the methods have confused the message. *AIDS*. 2013 Oct;27 Suppl 1:S45-53.
 312. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, Nakamura YM, Godbole SV, Panchia R, Sanne I, Weinstein MC, Losina E, Mayer KH, Chen YQ, Wang L, McCauley M, Gamble T, Seage GR 3rd, **Cohen MS**, Freedberg KA. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med*. 2013 Oct 31;369(18):1715-25.
 313. Peletz R, Mahin T, Elliott M, Harris MS, Chan KS, **Cohen MS**, Bartram JK, Clasen TF. Water, sanitation, and hygiene interventions to improve health among people living with HIV/AIDS: a systematic review. *AIDS*. 2013 Oct 23;27(16):2593-601.
 314. **Cohen MS**, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? *Lancet*. 2013 Nov 2;382(9903):1515-24. Review.
 315. Fogel JM, Wang L, Parsons TL, Ou SS, Piwowar-Manning E, Chen Y, Mudhune VO, Hosseinipour MC, Kumwenda J, Hakim JG, Chariyalertsak S, Panchia R, Sanne I, Kumarasamy N, Grinsztejn B, Makhema J, Pilotto J, Santos BR, Mayer KH, McCauley M, Gamble T, Bumpus NN, Hendrix CW, **Cohen MS**, Eshleman SH. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). *J Infect Dis*. 2013 Nov 15;208(10):1624-8. Epub 2013 Aug 1.
 316. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfafferott K, Aasa-Chapman MM, Pellegrino P, Williams I, **Cohen MS**, Gao F, Shaw GM, Hahn BH, Ochsenbauer C, Kappes JC, Borrow P. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. *Retrovirology*. 2013 Dec 3;10:146.
 317. Phiri S, Zadrozny S, Weiss HA, Martinson F, Nyirenda N, Chen CY, Miller WC, **Cohen MS**, Mayaud P, Hoffman IF. Etiology of Genital Ulcer Disease and Association with HIV Infection in Malawi. *Sex Transm Dis*. 2013 Dec;40(12):923-8.
 318. Walensky RP, **Cohen MS**, Freedberg KA. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. *N Engl J Med*. 2014 Feb 6;370(6):581-2. No abstract available.
 319. Burns DN, Degruittola V, Pilcher CD, Kretzschmar M, Gordon CM, Flanagan EH, Duncombe C, **Cohen MS**. Toward an Endgame: Finding and Engaging People Unaware of Their HIV-1 Infection in Treatment and Prevention. *AIDS Res Hum Retroviruses*. 2014 Feb 11.
 320. Gay C, Adimora A, Miller W, **Cohen MS**. Surveillance of HIV in the United States and England, Scotland, and Northern Ireland: what have we learned and what do we do about it? *Sex Transm Dis*. 2014 Apr;41(4):266-7. PubMed PMID: 24622639.
 321. Grinsztejn B, Hosseinipour MC, Ribaldo HJ, Swindells S, Eron J, Chen YQ, Wang L, Ou SS, Anderson M, McCauley M, Gamble T, Kumarasamy N, Hakim JG, Kumwenda J, Pilotto JH, Godbole SV, Chariyalertsak S, de Melo MG, Mayer KH, Eshleman SH, Piwowar-Manning E, Makhema J, Mills LA, Panchia R, Sanne I, Gallant J, Hoffman I, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Havlir D, **Cohen MS**; HPTN 052-ACTG Study Team. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis*. 2014 Apr;14(4):281-90. Epub 2014 Mar 4. Erratum in: *Lancet Infect Dis*. 2014 Apr;14(4):269. PubMed PMID: 24602844; PubMed Central PMCID: PMC4144040.
 322. Powers KA, **Cohen MS**. Acute HIV-1 infection in sub-Saharan Africa: a common occurrence overlooked. *AIDS*. 2014 Jun 1;28(9):1365-7. PubMed PMID: 24959964.
 323. Marzinke MA, Breaud A, Parsons TL, **Cohen MS**, Piwowar-Manning E, Eshleman SH, Clarke W. The development and validation of a method using high-resolution mass spectrometry (HRMS) for

- the qualitative detection of antiretroviral agents in human blood. *Clin Chim Acta*. 2014 Jun 10;433:157-68. Epub 2014 Mar 22. PubMed PMID: 24661980; PubMed Central PMCID: PMC4039613.
324. Adimora AA, Ramirez C, Schoenbach VJ, **Cohen MS**. Policies and politics that promote HIV infection in the Southern United States. *AIDS*. 2014 Jun 19;28(10):1393-7. PubMed PMID: 24556871.
325. Dennis AM, Herbeck JT, Brown AL, Kellam P, de Oliveira T, Pillay D, Fraser C, **Cohen MS**. Phylogenetic studies of transmission dynamics in generalized HIV epidemics: an essential tool where the burden is greatest? *J Acquir Immune Defic Syndr*. 2014;67(2):181-95. Epub 2014/07/01. PubMed PMID: 24977473; PubMed Central PMCID: PMC4304655.
326. Marrazzo JM, del Rio C, Holtgrave DR, **Cohen MS**, Kalichman SC, Mayer KH, Montaner JS, Wheeler DP, Grant RM, Grinsztejn B, Kumarasamy N, Shoptaw S, Walensky RP, Dabis F, Sugarman J, Benson CA; International Antiviral Society-USA Panel. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. *JAMA*. 2014 Jul 23-30;312(4):390-409. Erratum in: *JAMA*. 2014 Aug 13;312(6):652. *JAMA*. 2014 Jul 23-30;312(4):403. PubMed PMID: 25038358.
327. Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, Cai F, Hwang KK, Song H, Zhou T, Lynch RM, Alam SM, Moody MA, Ferrari G, Berrong M, Kelsoe G, Shaw GM, Hahn BH, Montefiori DC, Kamanga G, **Cohen MS**, Hraber P, Kwong PD, Korber BT, Mascola JR, Kepler TB, Haynes BF. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. *Cell*. 2014;158(3):481-91. Epub 2014/07/30. PubMed PMID: 25065977; PubMed Central PMCID: PMC4150607.
328. Muessig KE, **Cohen MS**. Advances in HIV prevention for serodiscordant couples. *Current HIV/AIDS reports*. 2014;11(4):434-46. Epub 2014/08/26. PubMed PMID: 25145645; PubMed Central PMCID: PMC4267973.
329. Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, **Cohen MS**, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR, Haynes BF. Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. *Cell host & microbe*. 2014;16(3):304-13. Epub 2014/09/12. PubMed PMID: 25211073; PubMed Central PMCID: PMC4163498.
330. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, **Cohen MS**, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. *Nature*. 2014;514(7523):455-61. Epub 2014/10/09. PubMed PMID: 25296255.
331. Powers KA, Kretzschmar ME, Miller WC, **Cohen MS**. Impact of early-stage HIV transmission on treatment as prevention. *Proceedings of the National Academy of Sciences of the United States of America*. 2014 Nov 11;111(45):15867-8. Epub 2014/11/05. PubMed PMID: 25368195; PMCID: PMC4234559.
332. Rosenberg NE, Pilcher CD, Busch MP, **Cohen MS**. How can we better identify early HIV infections? *Curr Opin HIV AIDS*. 2015 Jan;10(1):61-8. Epub 2014/11/13. PubMed PMID: 25389806.
333. Rahangdale L, De Paris K, Kashuba AD, Nelson JA, Cottrell M, Sykes C, Emerson C, Young SL, Stevens T, Patterson KB, **Cohen MS**. Immunologic, Virologic, and Pharmacologic Characterization of the Female Upper Genital Tract in HIV-infected women. *J Acquir Immune Defic Syndr*. 2015 Apr 1;68(4):420-4. Epub 2014/12/17. PubMed PMID: 25501615.
334. Pillay D, Herbeck J, **Cohen MS**, de Oliveira T, Fraser C, Ratmann O, Brown AL, Kellam P; PANGEA-HIV Consortium. PANGEA-HIV: Phylogenetics for Generalised Epidemics in Africa. *Lancet Infect Dis*. 2015 March;15(3):259-61. No abstract available. PMID: 25749217.

335. Nicol MR, Emerson CW, Prince HM, Nelson JA, Fedoriw Y, Sykes C, Geller EJ, Patterson KB, **Cohen MS**, Kashuba AD. Models for Predicting Effective HIV Chemoprevention in Women. *J Acquir Immune Defic Syndr*. 2015 Apr 1;68(4):369-76. Epub 2014/12/17. PubMed PMID: 25501616.
336. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, Joyce MG, Lingwood D, Soto C, Bailer RT, Ernandes MJ, Kong R, Longo NS, Louder MK, McKee K, O'Dell S, Schmidt SD, Tran L, Yang Z, Druz A, Luongo TS, Moquin S, Srivatsan S, Yang Y, Zhang B, Zheng A, Pancera M, Kirys T, Georgiev IS, Gindin T, Peng HP, Yang AS; NISC Comparative Sequencing Program, Mullikin JC, Gray MD, Stamatatos L, Burton DR, Koff WC, **Cohen MS**, Haynes BF, Casazza JP, Connors M, Corti D, Lanzavecchia A, Sattentau QJ, Weiss RA, West AP Jr, Bjorkman PJ, Scheid JF, Nussenzweig MC, Shapiro L, Mascola JR, Kwong PD. Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. *Cell*. 2015 Jun 4;161(6):1280-92. Epub 2015 May 21. PMID: 26004070.
337. Cope AB, Powers KA, Kuruc JD, Leone PA, Anderson JA, Ping LH, Kincer LP, Swanstrom R, Mobley VL, Foust E, Gay CL, Eron JJ, **Cohen MS**, Miller WC. Ongoing HIV Transmission and the HIV Care Continuum in North Carolina. *PLoS One*. 2015 June 4;10(6):e0127950. eCollection 2015. PMID: 26042804.
338. Safren SA, Mayer KH, Ou SS, McCauley M, Grinsztejn B, Hosseinipour MC, Kumarasamy N, Gamble T, Hoffman I, Celentano D, Chen YQ, **Cohen MS**; HPTN 052 Study Team. Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples. *J Acquir Immune Defic Syndr*. 2015 June 1;69(2):234-40. PMID: 26009832.
339. Bednar MM, Hauser BM, Ping LH, Dukhovlinova E, Zhou S, Arrildt KT, Hoffman IF, Eron JJ, **Cohen MS**, Swanstrom R. R5 Macrophage-Tropic HIV-1 in the Male Genital Tract. *J Virol*. 2015 Oct;89(20):10688-92. Epub 2015 Jul 29. PMID: 26223642.
340. Joseph SB, Swanstrom R, Kashuba AD, **Cohen MS**. Bottlenecks in HIV-1 Transmission: Insights from the Study of Founder Viruses. *Nat Rev Microbiol*. 2015 July;13(7):414-25. Epub 2015 June 8. PMID: 26052661.
341. Smith MK, Westreich D, Liu H, Zhu L, Wang L, He W, Zhou J, Miller WC, **Cohen MS**, Wang N. Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China 2006 to 2012. *Clin Infect Dis*. 2015 Jul 1;61(1):111-9. Epub 2015 Mar 13. PMID: 25770173.
342. Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, **Cohen MS**, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. *Cell Host Microbe*. 2015 Sep 9;18(3):354-62. PMID: 26355218.
343. Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, Schnell G, Sturdevant CB, Kincer LP, Mallewa M, Heyderman RS, Rie AV, **Cohen MS**, Spudich S, Price RW, Montefiori DC, Swanstrom R. Phenotypic Correlates of HIV-1 Macrophage Tropism. *J Virol*. 2015 Nov;89(22):11294-311. Epub 2015 Sep 2. PMID: 26339058.
344. Seña AC, Zhang XH, Li T, Zheng HP, Yang B, Yang LG, Salazar JC, **Cohen MS**, Moody MA, Radolf JD, Tucker JD. A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. *BMC Infect Dis*. 2015 Oct 28;15:479. PMID: 26511465.
345. Dumond JB, Yang KH, Kendrick R, Reddy YS, Kashuba AD, Troiani L, Bridges AS, Fiscus SA, Forrest A, **Cohen MS**. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells. *Antimicrob Agents Chemother*. 2015 Oct;59(10):6395-401. Epub 2015 Aug 3. PMID: 26239974.

346. Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, **Cohen MS**, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. *J Clin Invest*. 2015 Nov 2;125(11):4077-90. Epub 2015 Sep 28. PMID: 26413868.
347. Rutstein SE, Sellers CJ, Ananworanich J, **Cohen MS**. The HIV treatment cascade in acutely infected people: informing global guidelines. *Curr Opin HIV AIDS*. 2015 Nov;10(6):395-402. PMID: 26371460.
348. **Cohen MS**, Powers KA. Let's treat everyone with HIV now: what happens next? *Lancet HIV*. 2016 Mar;3(3):e109-10. Epub 2016 Feb 8. No abstract available. PMID: 26939733.
349. Fogel JM, Hudelson SE, Ou SS, Hart S, Wallis C, Morgado MG, Saravanan S, Tripathy S, Hovind L, Piwowar-Manning E, Sabin D, McCauley M, Gamble T, Zhang XC, Eron JJ, Gallant JE, Kumwenda J, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim J, Badal-Faesen S, Akelo V, Hosseinipour MC, Santos BR, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Mayer KH, Chen YQ, **Cohen MS**, Eshleman SH. Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. *J Acquir Immune Defic Syndr*. 2016 Jul 1;72(3):304-9. PMID: 26859828.
350. Fraser H, Mukandavire C, Martin N, Hickman M, **Cohen MS**, Miller WC, Vickerman P. HIV treatment as prevention among people who inject drugs – a re-evaluation of the evidence. *Int J Epidemiol*. 2016 Aug 14. pii: dyw180. [Epub ahead of print]. PMID: 27524816.
351. Wang AL, Peng RR, Tucker JD, Chakraborty H, **Cohen MS**, Chen XS. Optimizing Partner Notification Programs for Men Who Have Sex with Men: Factorial Survey Results from South China. *PLoS One*. 2016 Jul 27;11(7):e0157749. eCollection 2016. PMID: 27462724
352. **Cohen MS**, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR; HPTN 052 Study Team. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med*. 2016 Sep;375(9):830-9. [Epub 2016 Jul 18]. PMID: 27424812
353. Moody MA, Pedroza-Pacheco I, Vandergrift NA, Chui C, Lloyd KE, Parks R, Soderberg KA, Ogbé AT, **Cohen MS**, Liao H, Gao F, McMichael AJ, Montefiori DC, Verkoczy L, Kelsoe G, Huang J, Shea PR, Connors M, Borrow P, Haynes BF. Immune perturbations in HIV-1-infected individuals who make broadly reactive neutralizing antibodies. *Sci Immunol*. 2016 Jul 29;1:aag0851. PMID: 28783677.
354. **Cohen M**, Eshleman S, McCauley M, Chen Y. Antiretroviral Therapy to Prevent HIV Acquisition: Limits of Estimation From a Population Cohort. *Clin Infect Dis*. 2016 Dec 15;63(12):1679-1680. Epub 2016 Sep 29. PMID: 27694481.
355. Eshleman SH, Hudelson SE, Redd AD, Swanstrom R, Ou SS, Zhang XC, Ping LH, Piwowar-Manning E, Porcella SF, Sievers MF, Martens CA, Bruno D, Dukhovlina E, McCauley M, Gamble T, Fogel JM, Sabin D, Quinn TC, Gunde L, Maliwichi M, Nhando N, Akelo V, Moyo S, Panchia R, Kumarasamy N, Chotirosniramit N, Melo MG, Pilotto J, Grinsztejn B, Mayer K, Chen YQ, Hughes JP, **Cohen MS**. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. *J Acquir Immune Defic Syndr*. 2017 Jan 1;74(1):112-116. PMID: 27532476 [PubMed - in process].
356. Williams LD, Ofek G, Schätzle S, McDaniel JR, Lu X, Nicely NI, Wu L, Lougheed CS, Bradley T, Louder MK, McKee K, Bailer RT, O'Dell S, Georgiev IS, Seaman MS, Parks RJ, Marshall DJ, Anasti K, Yang G, Nie X, Tumba NL, Wiehe K, Wagh K, Korber B, Kepler TB, Munir Alam S, Morris L, Kamanga G, **Cohen MS**, Bonsignori M, Xia SM, Montefiori DC, Kelsoe G, Gao F, Mascola JR, Moody MA, Saunders KO, Liao HX, Tomaras GD, Georgiou G, Haynes BF. Potent

- and broad HIV-neutralizing antibodies in memory B cells and plasma. *Sci Immunol*. 2017 Jan 27;2(7). PMID: 28783671.
357. Gilbert PB, Juraska M, Decamp AC, Karuna S, Edupuganti S, Mgodini N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kocher N, Wang J, Eshleman SH, Mayer KH, Margaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, **Cohen MS**, Corey L. Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Conception Efficacy Trials. *Statistical Communications in Infectious Diseases*. Epub 2017 Jun 6.
 358. Fraser H, Mukandavire C, Martin NK, Hickman M, **Cohen MS**, Miller WC, Vickerman P. *Int J Epidemiol*. 2017 Apr 1;46(2):466-478. PMID: 27524816 [PubMed - in process].
 359. Guzzo C, Ichikawa D, Park C, Phillips D, Liu Q, Zhang P, Kwon A, Miao H, Lu J, Rehm C, Arthos J, Cicala C, **Cohen MS**, Fauci AS, Kehrl JH, Lusso P. *Sci Immunol*. 2017 May 12;2(11). pii: eaam7341. PMID: 28763793.
 360. Alam SM, Ausedat B, Vohra Y, Ryan Meyerhoff R, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Scarce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, Abdool-Karim SS, **Cohen M**, Liao HX, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, Haynes BF. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. *Sci Transl Med*. 2017 Mar 15;9(381). PMID: 28298421 [PubMed - in process].
 361. Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Ausedat B, Walkowicz WE, Hwang KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, **Cohen MS**, Hraber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. *Sci Transl Med*. 2017 Mar 15;9(381). PMID: 28298420 [PubMed - in process].
 362. Mangal TD; UNAIDS Working Group on CD4 Progression and Mortality Amongst HIV Seroconverters including the CASCADE Collaboration in EuroCoord. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. *AIDS*. 2017 May 15;31(8):1073-1082. PMID: 28301424 [PubMed - in process].
 363. Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, McCauley M, Gamble T, Gallant JE, Hosseinipour MC, Kumarasamy N, Hakim JG, Kalonga B, Pilotto JH, Grinsztejn B, Godbole SV, Chotirosniramit N, Santos BR, Shava E, Mills LA, Panchia R, Mwelase N, Mayer KH, Chen YQ, **Cohen MS**, Fogel JM. Virologic outcomes in early antiretroviral treatment: HPTN 052. *HIV Clin Trials*. 2017 May;18(3):100-109. Epub 2017 Apr 7. PMID: 28385131.
 364. Palumbo PJ, Wilson EA, Piwowar-Manning E, McCauley M, Gamble T, Kumwenda N, Makhema J, Kumarasamy N, Chariyalertsak S, Hakim JG, Hosseinipour MC, Melo MG, Godbole SV, Pilotto JH, Grinsztejn B, Panchia R, Chen YQ, **Cohen MS**, Eshleman SH, Fogel JM. Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. *PLoS One*. 2017 May 8;12(5):e0177281. eCollection 2017. PMID: 28481902 [PubMed - in process].
 365. Smith MK, Miller WC, Liu H, Ning C, He W, **Cohen MS**, Wang N. Effects of patient load and travel distance on HIV transmission in rural China: Implications for treatment as prevention. *PLoS One*. 2017 May 31;12(5):e0177976. eCollection 2017. PMID: 28562661 [PubMed - in process].
 366. Rutstein SE, Ananworanich J, Fidler S, Johnson C, Sanders EJ, Sued O, Saez-Cirion A, Pilcher CD, Fraser C, **Cohen MS**, Vitoria M, Doherty M, Tucker JD. Clinical and public health implications of acute and early HIV detection and treatment: a scoping review. *J Int AIDS Soc*. 2017 Jun 28;20(1):1-13. PMID: 28691435 [PubMed - in process].
 367. Greer AE, Ou SS, Wilson E, Piwowar-Manning E, Forman MS, McCauley M, Gamble T, Ruangyuttikarn C, Hosseinipour MC, Kumarasamy N, Nyirenda M, Grinsztejn B, Pilotto JH, Kosashunhanan N, Gonçalves de Melo M, Makhema J, Akelo V, Panchia R, Badal-Faesen S, Chen

- YQ, **Cohen MS**, Eshleman SH, Thio CL, Valsamakis A. A Comparison of Hepatitis B Virus Infection in HIV-infected and HIV-uninfected Participants Enrolled in a Multi-National Clinical Trial: HPTN 052. *J Acquir Immune Defic Syndr*. 2017 Jul 26. [Epub ahead of print]. PMID: 28749822.
368. Wong NS, Mao J, Cheng W, Tang W, **Cohen MS**, Tucker JD, Xu H. HIV Linkage to Care and Retention in Care Rate Among MSM in Guangzhou, China. *AIDS Behav*. 2017 Aug 28. PMID: 28849284.
369. Fogel JM, Piwovar-Manning E, Debevec B, Walsky T, Schlusser K, Laeyendecker O, Wilson EA, McCauley M, Gamble T, Tegha G, Soko D, Kumwenda J, Hosseinipour MC, Chen YQ, **Cohen MS**, Eshleman SH. Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays. *J Acquir Immune Defic Syndr*. 2017 Aug 1;75(4):426-430. PMID: 28471839.
370. **Cohen MS**, Corey L. Broadly neutralizing antibodies to prevent HIV-1. *Science*. 2017 Oct 6;358(6359):46-47. PMID: 28983040.
371. Wood D, Lancaster KE, Boily MC, Powers KA, Donnell D, **Cohen MS**, Dimitrov DT. Recruitment of Female Sex Workers in HIV Prevention Trials: Can Efficacy Endpoints Be Reached More Efficiently?. *J Acquir Immune Defic Syndr*. 2017 Nov 28. PMID: 29206720.
372. Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe E, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao HX, Haynes BF, Robb ML, Parkin N, Santos BR, Garrett N, Price MA, Nanche D, Duerr AC; CEPHIA group, Keating S, Hampton D, Facente S, Marson K, Welte A, Pilcher CD, **Cohen MS**, Tomaras GD. Computational analysis of antibody dynamics identifies recent HIV-1 infection. *JCI Insight*. 2017 Dec 21;2(24). PMID: 29263306.
373. Palumbo PJ, Fogel JM, Hudelson SE, Wilson EA, Hart S, Hovind L, Piwovar-Manning E, Wallis C, Papathanasopoulos MA, Morgado MG, Saravanan S, Tripathy S, Eron JJ, Gallant JE, Mph, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Pilotto JH, Kumwenda J, Akelo V, Godbole SV, Santos BR, Grinsztejn B, Panchia R, Chariyalertsak S, Makhema J, Badal-Faesen S, Chen YQ, **Cohen MS**, Eshleman SH. HIV Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy: HPTN 052. *J Acquir Immune Defic Syndr*. 2017 Dec 28. PMID: 29293156.
374. Song H, Giorgi EE, Ganusov VV, Cai F, Athreya G, Yoon H, Carja O, Hora B, Hraber P, Romero-Severson E, Jiang C, Li X, Wang S, Li H, Salazar-Gonzalez JF, Salazar MG, Goonetilleke N, Keele BF, Montefiori DC, **Cohen MS**, Shaw GM, Hahn BH, McMichael AJ, Haynes BF, Korber B, Bhattacharya T, Gao F. Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. *Nat Commun*. 2018 May 15;9(1):1928. PMID: 29765018.
375. Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, **Cohen MS**, Gilbert PB, Gray GE. Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. *AIDS Res Hum Retroviruses*. 2018 Aug;34(8):645-656. Epub 2018 Jun 19. PMID: 29732896.
376. **Cohen MS**. Treatment for HIV prevention, one couple at a time. *Lancet HIV*. 2018 Aug;5(8):e408-e409. Epub 2018 Jul 17. No abstract available. PMID: 30025680.
377. Coltart C, Hoppe A, Parker M, Dawson Liza, Amon JJ, Simwinga M, Geller G, Henderson G, Laeyendecker O, Tucker JD, Eba P, Novitsky V, Vandamme AM, Seely J, Dallabetta G, Harling G, Grabowski K, Godfrey-Faussett P, Fraser C, **Cohen MS**, Pillay D. Ethical considerations in global HIV phylogenetic research. *Lancet HIV*. 2018 Aug 30. PMID: 30174214.
378. Bradley T, Peppas D, Pedroza-Pacheco I, Li D, Cain DW, Henao R, Venkat V, Hora B, Chen Y, Vandergrift NA, Overman RG, Edwards RW, Woods CW, Tomaras GD, Ferrari G, Ginsburg GS, Connors M, **Cohen MS**, Moody MA, Borrow P, Haynes BF. RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. *Cell*. 2018 Oct 4;175(2):387-399.e17. PMID: 30270043.
379. Dumond JB, Greene SA, Prince HM, Chen J, Maas BL, Sykes C, Schauer AP, Blake K, Nelson JA, Gay CL, Kashuba AD, **Cohen MS**. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract. *Antivir Ther*. 2018 Oct 30. PMID: 30375984.

380. Dukhovlinova E, Masharsky A, Vasileva A, Porrello A, Zhou S, Toussova O, Verevochkin S, Akulova E, Frishman D, Montefiori D, Labranche C, Hoffman I, Miller W, **Cohen MS**, Kozlov AP, Swanstrom R. Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use. *AIDS Res Hum Retroviruses*. 2018 Oct;34(10):867-878. Epub 2018 Jul 30. PMID: 29756455.
381. Dennis AM, **Cohen MS**, Rucinski KB, Rutstein SE, Powers KA, Pasquale DK, Phiri S, Hosseinipour MC, Kamanga G, Nsona D, Massa C, Hoffman IF, Pettifor AE, Miller WC. HIV-1 transmission among persons with acute HIV-1 infection in Malawi: demographic, behavioral and phylogenetic relationships. *Clin Infect Dis*. 2018 Nov 26. [Epub ahead of print] PMID:30476007.
382. Landovitz RJ, Li S, Grinsztenjn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, **Cohen MS**, McCauley M, Eron JJ. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. *PLoS Med*. 2018 Nov 8;15(11):e1002690. PMID: 30408115.
383. Rose R, Hall M, Redd AD, Lamers S, Barbier AE, Porcella SF, Hudelson SE, Piwowar-Manning E, McCauley M, Gamble T, Wilson EA, Kumwenda J, Hosseinipour MC, Hakim JG, Kumarasamy N, Chariyalertsak S, Pilotto JH, Grinsztejn B, Mills LA, Makhema J, Santos BR, Chen YQ, Quinn TC, Fraser C, **Cohen MS**, Eshleman SH, Laeyendecker O. Phylogenetic methods inconsistently predict direction of HIV transmission among heterosexual pairs in the HPTN052 cohort. *J Infect Dis*. 2018 Dec 24.[Epub ahead of print] PMID: 30590741.
384. **Cohen MS**, Donnell D. Novel approaches for development of HIV pre-exposure prophylaxis (PrEP) agents. *J Infect Dis*. 2019 Jan 31. [Epub ahead of print] PMID: 30715403.
385. Greene SA, Chen J, Prince HMA, Sykes C, Schauer AP, Blake K, Nelson JAE, Gay CL, **Cohen MS**, Dumond JB. Population Modeling Highlights Drug Disposition Differences Between Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in the Blood and Semen. *Clin Pharmacol Ther*. 2019 Apr 19. [Epub ahead of print]. PMID: 31002391.
386. Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, **Cohen MS**, Currier JS. Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077. *Clin Infect Dis*. 2019 May 24. PMID: 31125395.
387. **Cohen MS**. Successful treatment of HIV eliminates sexual transmission. *Lancet*. 2019 May 2. pii: S0140-6736(19)30701-9. [Epub ahead of print] No abstract available. PMID: 31056290.
388. **Cohen MS**. Treatment for HIV prevention, one couple at a time. *Lancet HIV*. 2018 Aug;5(8):e408-e409. Epub 2018 Jul 17. No abstract available. PMID: 30025680
389. **Cohen MS**, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. *Journal of the International AIDS Society*. 2019 Aug 22. PMID: 31468737
390. **Cohen MS**, Gamble T, McCauley M. Prevention of HIV Transmission and the HPTN 052 Study. *Annual Review of Medicine*. 2020 Jan 27. PMID: 31652410
391. Zhang Y, Wymant C, Laeyendecker O, Grabowski MK, **Cohen MS**, et al. Evaluation of phylogenetic methods for inferring the direction of HIV transmission: HPTN 052. *Clin Infect Dis*. 2020 Jan 10. PMID: 31922537
392. Elliott T, Sanders EJ, Doherty M, Ndung'u T, **Cohen M**, Patel P, Cairns G, Rutstein SE, Ananworanich J, Brown C, Fidler S. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. *J Int AIDS Soc*. 2019 Dec;22(12):e25419. doi: 10.1002/jia2.25419. PMID: 31850686
393. Topazian HM, Stoner MCD, Edwards JK, Kahn K, Gómez-Olivé FX, Twine R, Hughes JP, **Cohen MS**, Pettifor A. Variations in HIV Risk by Young Women's Age and Partner Age Disparity in Rural

- South Africa (HPTN 068). *J Acquir Immune Defic Syndr*. 2020 Apr 1;83(4):350-356. PMID: 31904708
394. Reeves DB, Huang Y, Duke ER, Mayer BT, Cardozo-Ojeda EF, Boshier FA, Swan DA, Rolland M, Robb ML, Mascola JR, **Cohen MS**, Corey L, Gilbert PB, Schiffer JT. Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. *PLoS Comput Biol*. 2020 Feb 21;16(2):e1007626. PMID: 32084132
395. Cubero EM, Ogbe A, Pedroza-Pacheco I, **Cohen MS**, Haynes BF, Borrow P, Peppas D. Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. *Front Immunol*. 2020 Feb 18;11:156. PMID: 32132995
396. Margolis DM, Archin NM, **Cohen MS**, Eron JJ, Ferrari G, Garcia JV, Gay CL, Goonetilleke N, Joseph SB, Swanstrom R, Turner AW, Wahl A. Curing HIV: Seeking to Target and Clear Persistent Infection. *Cell*. 2020 Apr 2;181(1):189-206. PMID: 32220311
397. Council OD, Zhou S, McCann CD, Hoffman I, Tegha G, Kamwendo D, Matoga M, Kosakovsky Pond SL, **Cohen MS**, Swanstrom R. Deep Sequencing Reveals Compartmentalized HIV-1 in the Semen of Men With and Without STI-Associated Urethritis. *J Virol*. 2020 Apr 8. pii: JVI.00151-20. PMID: 32269129
398. **Cohen MS**, Corey L. Combination prevention for COVID-19. *Science*. 2020 May 8;368(6491):551. Hydroxychloroquine for the Prevention of Covid-19 - Searching for Evidence. PMID: 32381692
399. **Cohen MS**. Hydroxychloroquine for the Prevention of Covid-19 – Searching for Evidence. *N Engl J Med*. 2020 Jun 3;NEJMe2020388. PMID: 32492298
400. Marovich M, Mascola JR, **Cohen MS**. Monoclonal Antibodies for Prevention and Treatment of COVID-19. *JAMA*. 2020 Jun 15. PMID: 32539093
401. Deming ME, Michael NL, Robb M, **Cohen MS**, Neuzil KM. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. *N Engl J Med*. 2020 Jul 1. PMID: 32610006
402. Landovitz RJ, Li S, Eron JJ Jr, Grinsztejn B, Dawood H, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. *Lancet HIV*. 2020 Jul;7(7):e472-e481. PMID: 32497491
403. Zhou S, Sizemore S, Moeser M, Zimmerman S, Samoff E, Mobley V, Frost S, Cressman A, Clark M, Skelly T, Kelkar H, Veluvolu U, Jones C, Eron J, **Cohen M**, Nelson JAE, Swanstrom R, Dennis AM. Near Real-Time Identification of Recent HIV Transmissions, Transmitted Drug Resistance Mutations, and Transmission Networks by MPID-NGS in North Carolina. *J Infect Dis*. 2020 Jul 14:jiaa417. doi: 10.1093/infdis/jiaa417. Epub ahead of print. PMID: 32663847.
404. Rutstein SE, Smith DK, Dalal S, Baggaley RC, **Cohen MS**. Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. *Lancet HIV*. 2020 Oct;7(10):e721-e730. doi: 10.1016/S2352-3018(20)30203-4. Epub 2020 Aug 27. PMID: 32861269; PMCID: PMC7541752.
405. **Cohen MS**, Landovitz R. Assessing the Role of Long Acting Cabotegravir Pre-Exposure Prophylaxis of HIV: Opportunities and Aspirations. *J Infect Dis*. 2020 Sep 3:jiaa555. doi: 10.1093/infdis/jiaa555. Epub ahead of print. PMID: 32882042.
406. Matoga M, Chen JS, Kudowa E, Kamanga G, Mapanje C, Massa C, Ndalama B, Bonongwe N, Nyirenda N, Mathiya E, Jere E, Ngoma E, Chagomerana M, Phiri S, Powers KA, Miller WC, **Cohen MS**, Hoffman IF. Syndromes Associated with Sexually Transmitted Infections in Lilongwe, Malawi: Burden and Trends, 2006-2015. *Sex Transm Dis*. 2020 Sep 8. doi: 10.1097/OLQ.0000000000001278. Epub ahead of print. PMID: 32925596.
407. Celum C, Barnabas R, **Cohen MS**, Collier A, El-Sadr W, Holmes KK, Johnston C, Piot P. Covid-19, Ebola, and HIV - Leveraging Lessons to Maximize Impact. *N Engl J Med*. 2020 Oct 7. doi: 10.1056/NEJMp2022269. Epub ahead of print. PMID: 33027565.
408. Chen JS, Matoga M, Massa C, Tegha G, Ndalama B, Bonongwe N, Mathiya E, Jere E, Banda G, Loftis AJ, Lancaster KE, Miller WC, Hoffman IF, **Cohen MS**. Effects of Urethritis on HIV in

- Semen: Implications for HIV Prevention and Cure. *Clin Infect Dis*. 2020 Oct 9;ciaa1529. doi: 10.1093/cid/ciaa1529. Epub ahead of print. PMID: 33033831.
409. Novitsky V, Zahralban-Steele M, Moyo S, Nkhisang T, Maruapula D, McLane MF, Leidner J, Bennett K; PANGEA Consortium, Wirth KE, Gaolathe T, Kadima E, Chakalisa U, Pretorius Holme M, Lockman S, Mmalane M, Makhema J, Gaseitsiwe S, DeGruttola V, Essex M. Mapping of HIV-1C Transmission Networks Reveals Extensive Spread of Viral Lineages Across Villages in Botswana Treatment-as-Prevention Trial. *J Infect Dis*. 2020 Oct 13;222(10):1670-1680. doi: 10.1093/infdis/jiaa276. PMID: 32492145.
410. Hora B, Gulzar N, Chen Y, Karagiannis K, Cai F, Su C, Smith K, Simonyan V, Shah SA, Ahmed M, Sanchez AM, Stone M, **Cohen MS**, Denny TN, Mazumder R, Gao F. Streamlined Subpopulation, Subtype, and Recombination Analysis of HIV-1 Half-Genome Sequences Generated by High-Throughput Sequencing. *mSphere*. 2020 Oct 14;5(5):e00551-20. doi: 10.1128/mSphere.00551-20. PMID: 33055255.
411. Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, Benkeser D, Brown ER, Carone M, Cho I, Donnell D, Fay MP, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Juraska M, Luedtke A, Nason M, Vandebosch A, Zhou H, **Cohen MS**, Corey L, Hartzel J, Follmann D, Gilbert PB. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. *Ann Intern Med*. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22. PMID: 33090877; PMCID: 7596738.
412. Moore JR, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Bekker LG, Mgodini NM, El-Sadr W, **Cohen MS**, Celum CL, Dimitrov D. Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression. *J Acquir Immune Defic Syndr*. 2020 Dec 1;85(4):423-429. doi: 10.1097/QAI.0000000000002481. PMID: 33136739.
413. Moore M, Boily MC, Mitchell KM, Donnell DD, **Cohen MS**, Dimitrov DT. Identifying Regions of Greatest Need for Ending the HIV Epidemic: A Plan for America. *J Acquir Immune Defic Syndr*. 2020 Dec 1;85(4):395-398. doi: 10.1097/QAI.0000000000002477. PMID: 33136735.
414. Mgodini NM, Takuva S, Edupuganti S, Karuna S, Andrew P, Lazarus E, Garnett P, Shava E, Mukwekwerere PG, Kochar N, Marshall K, Rudnicki E, Juraska M, Anderson M, Karg C, Tindale I, Greene E, Luthuli N, Baepanye K, Hural J, Gomez Lorenzo MM, Burns D, Miner MD, Ledgerwood J, Mascola JR, Donnell D, **Cohen MS**, Corey L; and the HVTN 703/HPTN 081 Team. A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa: baseline findings. *J Acquir Immune Defic Syndr*. 2021 Feb 11. doi: 10.1097/QAI.0000000000002649. Online ahead of print. PMID: 33587510
415. Edupuganti S, Mgodini N, Karuna ST, Andrew P, Rudnicki E, Kochar N, deCamp A, De La Grecca R, Anderson M, Karg C, Tindale I, Greene E, Broder GB, Lucas J, Hural J, Gallardo-Cartagena JA, Gonzales P, Frank I, Sobieszczyk M, Gomez Lorenzo MM, Burns D, Anderson PL, Miner MD, Ledgerwood J, Mascola JR, Gilbert PB, **Cohen MS**, Corey L; HVTN 704/HPTN 085 study group. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. *J Acquir Immune Defic Syndr*. 2021 Feb 11. doi: 10.1097/QAI.0000000000002639. Online ahead of print. PMID: 33587505
416. Huang Y, Naidoo L, Zhang L, Carpp LN, Rudnicki E, Randhawa A, Gonzales P, McDermott A, Ledgerwood J, Lorenzo MMG, Burns D, DeCamp A, Juraska M, Mascola J, Edupuganti S, Mgodini N, **Cohen M**, Corey L, Andrew P, Karuna S, Gilbert PB, Mngadi K, Lazarus E. Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. *EBioMedicine*. 2021 Jan 22;64:103203. doi: 10.1016/j.ebiom.2020.103203. Online ahead of print. PMID: 33493795
417. Follmann D, Fintzi J, Fay MP, Janes HE, Baden L, Sahly HE, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, **Cohen MS**,

- Corey L, Gilbert PB, Neuzil KM. Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials. medRxiv. 2020 Dec 14:2020.12.14.20248137. doi: 10.1101/2020.12.14.20248137. Preprint. PMID: 33336213
418. **Cohen MS**. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection. *N Engl J Med*. 2021 Jan 21;384(3):289-291. doi: 10.1056/NEJMe2034495. PMID: 33471984
419. Mitchell KM, Dimitrov D, Hughes JP, Moore M, Vittinghoff E, Liu A, **Cohen MS**, Beyrer C, Donnell D, Boily MC. Assessing the use of surveillance data to estimate the impact of prevention interventions on HIV incidence in cluster-randomized controlled trials. *Epidemics*. 2020 Dec;33:100423. doi: 10.1016/j.epidem.2020.100423. Epub 2020 Nov 20. PMID: 33285419
420. **Cohen MS**, Landovitz RJ. Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations. *J Infect Dis*. 2021 Jan 4;223(1):1-3. doi: 10.1093/infdis/jiaa555. PMID: 32882042 No abstract available.
421. Seneviratne HK, Hamlin AN, Li S, Grinsztejn B, Dawood H, Liu AY, Kuo I, Hosseinipour MC, Panchia R, Cottle L, Chau G, Adeyeye A, Rinehart AR, McCauley M, Eron JS, **Cohen MS**, Landovitz RJ, Hendrix CW, Bumpus NN. Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. *ACS Pharmacol Transl Sci*. 2021 Jan 21;4(1):226-239. doi: 10.1021/acspsci.0c00181. eCollection 2021 Feb 12. PMID: 33615175
422. Corey L, Gilbert PB, Juraska M, Montefiori DC, Morris L, Karuna ST, Edupuganti S, Mgodini NM, deCamp AC, Rudnicki E, Huang Y, Gonzales P, Cabello R, Orrell C, Lama JR, Laher F, Lazarus EM, Sanchez J, Frank I, Hinojosa J, Sobieszczyk ME, Marshall KE, Mukwekwerere PG, Makhema J, Baden LR, Mullins JI, Williamson C, Hural J, McElrath MJ, Bentley C, Takuva S, Gomez Lorenzo MM, Burns DN, Espy N, Randhawa AK, Kochar N, Piwowar-Manning E, Donnell DJ, Sista N, Andrew P, Kublin JG, Gray G, Ledgerwood JE, Mascola JR, **Cohen MS**; Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. HVTN 704/HPTN 085 and HVTN 703/HPTN 081 Study Teams. *N Engl J Med*. 2021 Mar 18;384(11):1003-1014. doi: 10.1056/NEJMoa2031738. PMID: 33730454
423. Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, McCauley M, Cummings V, Ahmed S, Haines CD, Bushman LR, Petropoulos C, Persaud D, Adeyeye A, Kofron R, Rinehart A, St Clair M, Rooney JF, Pryluka D, Coelho L, Gaur A, Middelkoop K, Phanuphak N, **Cohen MS**, Hendrix CW, Anderson P, Hanscom B, Donnell D, Landovitz RJ, Eshleman SH. Characterization of HIV infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. *J Infect Dis*. 2021 Mar 19;jiab152. doi: 10.1093/infdis/jiab152. Online ahead of print. PMID: 33740057
424. Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, **Cohen MS**, Corey L, Gilbert PB, Neuzil KM. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. *Ann Intern Med*. 2021 Apr 13. doi: 10.7326/M20-8149. Online ahead of print. PMID: 33844575
425. Jayaweera, D., Flume, P., Singer, N., **Cohen, M.**, Lachiewicz, A., Cameron, A., . . . Bauer, P. (2021). Prioritizing studies of COVID-19 and lessons learned. *Journal of Clinical and Translational Science*, 5(1), E106. doi:10.1017/cts.2021.784. PMID: 34192060
426. **Cohen MS**, Wohl DA, Fischer WA, Smith DM, Eron JJ. Outpatient Treatment of SARS-CoV-2 Infection to Prevent COVID-19 Progression. *Clin Infect Dis*. 2021 May 28:ciab494. doi: 10.1093/cid/ciab494. Online ahead of print. PMID: 34048568
427. **Cohen MS**, Nirula A, Mulligan MJ, Novak RM, Marovich M, Yen C, Stemer A, Mayer SM, Wohl D, Brengle B, Montague BT, Frank I, McCulloh RJ, Fichtenbaum CJ, Lipson B, Gabra N, Ramirez JA, Thai C, Chege W, Gomez Lorenzo MM, Sista N, Farrior J, Clement ME, Brown ER, Custer KL, Van Naarden J, Adams AC, Schade AE, Dabora MC, Knorr J, Price KL, Sabo J, Tuttle JL, Klekotka P, Shen L, Skovronsky DM; BLAZE-2 Investigators. Effect of Bamlanivimab vs Placebo on

- Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. *JAMA*. 2021 Jun 3. doi: 10.1001/jama.2021.8828. Online ahead of print. PMID: 34081073
428. Mollan KR, Eron JJ, Krajewski TJ, Painter W, Duke ER, Morse CG, Goecker EA, Premkumar L, Wolfe CR, Szewczyk LJ, Alabanza PL, Loftis AJ, Degli-Angeli EJ, Brown AJ, Dragavon JA, Won JJ, Keys J, Hudgens MG, Wohl DA, **Cohen MS**, Baric RS, Coombs RW, Sheahan TP, Fischer WA. SARS-CoV-2 infectious virus, viral RNA in nasopharyngeal swabs, and serostatus of symptomatic COVID-19 outpatients in the United States. *medRxiv*. 2021 Jun 1:2021.05.28.21258011. doi: 10.1101/2021.05.28.21258011. PMID: 34100024
 429. Dennis AM, Frost SDW, Enders K, Cressman AE, Volz E, Adams N, Miller WC, **Cohen MS**, Mobley V, Samoff E, Eron JJ. HIV-1 Transmission linkages among persons with incident infection to inform public health surveillance. *EClinicalMedicine*. 2021 Jun 17;37:100968. doi: 10.1016/j.eclinm.2021.100968. eCollection 2021 Jul. PMID: 34195581
 430. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, **Cohen MS**, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention. *medRxiv*. 2021 Jun 17:2021.06.14.21258567. doi: 10.1101/2021.06.14.21258567. PMID: 34159344
 431. O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, **Cohen MS**, Hurt CB, Burwen DR, Marovich MA, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. Subcutaneous REGEN-COV Antibody Combination in Early SARS-CoV-2 Infection. *medRxiv*. 2021 Jun 14:2021.06.14.21258569. doi: 10.1101/2021.06.14.21258569. PMID: 34159343
 432. Fischer W, Eron JJ, Holman W, **Cohen MS**, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, an Oral Antiviral Treatment for COVID-19. *medRxiv*. 2021 Jun 17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. PMID: 34159342
 433. Huang Y, Zhang L, Eaton A, Mkhize NN, Carpp LN, Rudnicki E, DeCamp A, Juraska M, Randhawa A, McDermott A, Ledgerwood J, Andrew P, Karuna S, Edupuganti S, Mgodini N, **Cohen M**, Corey L, Mascola J, Gilbert PB, Morris L, Montefiori DC. Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. *Hum Vaccin Immunother*. 2021 Jul 2:1-10. doi: 10.1080/21645515.2021.1908030. PMID: 34213402
 434. Corey L, Beyrer C, **Cohen MS**, Michael NL, Bedford T, Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. *N Engl J Med*. 2021 Aug 5;385(6):562-566. doi: 10.1056/NEJMsb2104756. PMID: 34347959
 435. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, **Cohen MS**, McCauley M, Grinsztejn B; HPTN 083 Study Team. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. *N Engl J Med*. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016. PMID: 34379922 Clinical Trial.

436. O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, **Cohen MS**, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. *N Engl J Med*. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682. Epub 2021 Aug 4. PMID: 34347950

Editorials

1. **Cohen MS**. A new deal in antibacterial therapy: The reductionist approach. *Hospital Pharmacy*. 19:592-594, 1984.
2. **Cohen MS**. The great cephalosporin wars. *European Journal of Clinical Microbiology* 3:177-179, 1984.
3. **Cohen MS**. Antibiotic Therapy 1985: What are the challenges? *Hosp. Form.* 20:1247-1249, 1985.
4. **Cohen MS**. Antibiotic therapy in the neutropenic host: How many drugs are enough? *Infect. Med.* 4:237-246, 1987.
5. **Cohen MS**. Stress, the immune system and infections. *Infect Med.* 8:18, 1991.
6. **Cohen MS**, Dallabetta G, Laga M, Holmes KK. A new deal in HIV prevention: lessons from the global approach. *Ann Intern Med.* 120:340-341, 1994.
7. Hassett DJ, **Cohen MS**. RecA versus Catalase: Who's on First? *J Clin Invest.* March, 1995.
8. Kenney SC, **Cohen MS**. A review of human herpesvirus-6 infections. Editorial Comment. *Infections in Medicine* 12:399, 1995.
9. **Cohen MS**, Miller WC. Sexually transmitted diseases and human immunodeficiency virus infection: cause, effect, or both? *Int J Infect Dis* 3(1):1-4, 1998.
10. **Cohen MS**, Ping G, Fox K, Henderson G. Sexually transmitted diseases in the People's Republic of China in Y2K: Back to the future. *Sex Transm Dis* 27(3):143-5, 2000.
11. **Cohen MS**. Preventing sexual transmission of HIV—new ideas from sub-Saharan Africa. *N Engl J Med* 342(13):970-2, 2000.
12. **Cohen MS** and Pilcher, C. Amplified HIV transmission and new approaches to HIV prevention. *J Infectious Diseases* 191:1391-1393, 2005.
13. **Cohen MS**, Kashuba A and Gay C. HIV antiretroviral prophylaxis: a cautionary note. *Clin Infect Dis* 41: 514-16, 2005.
14. **Cohen MS**. When people with HIV get syphilis: Triple Jeopardy. *STD* 33:149-50, 2006.
15. **Cohen MS.**, Hawkes S, and Maybe D. Syphilis returns to China with a vengeance. *STD* 33:25-6, 2007.
16. **Cohen MS** and Kashuba A. HIV pre-exposure prophylaxis in rhesus macaques: Caution optimism for HIV prevention in humans *PLOS Medicine* 5:30, 2008.
17. **Cohen, MS**. HIV Postexposure prophylaxis after sexual assault: why is it so hard to accomplish. *Sex Transm. Dis.* 35: 979-80, 2008.
18. **Cohen MS**. HIV treatment as prevention and "the Swiss statement": in for a dime, in for a dollar? *Clin Infect Dis.* 1;51(11):1323-4, 2010.

19. **Cohen MS.** HIV treatment as prevention: to be or not to be? *J Acquir Immune Defic Syndr.* 1;55(2):137-8, 2010.
20. **Cohen MS,** Eron J, Soderberg K Jr, McMichael A. High clade C HIV viremia: How did we get here and where are we going. *AIDS* 25:1543-5, 2011.
21. Mastro TD, **Cohen MS,** Rees H. Antiretrovirals for safer conception for HIV-negative women and their HIV-1-infected male partners: how safe and how available? *AIDS.* 25:2049-51, 2011.
22. **Cohen MS,** Eron JJ Jr Acyclovir treatment for human immunodeficiency virus-1: is the “juice worth the squeeze?” *Sex Transm Dis.* 38:410-2. 2011.
23. El-Sadr WM, Gamble TR, **Cohen MS.** Linkage From **HIV** Testing to Care: A Positive Test Often Leads Nowhere. *Sex Transm Dis.* 2013 Jan;40(1):26-7.
24. El-Sadr WM, Gamble TR, **Cohen MS.** *Sex Transm Dis.* 2013 Jan;40(1):26-7.
25. **Cohen MS.** Classical Sexually Transmitted Diseases Drive the Spread of HIV-1: Back to the Future. *J Infect Dis.* 206(1):1-2. Epub 2012 Apr 19, 2012.

Books

1. Henderson GE and **Cohen MS.** *The Chinese Hospital: A Socialist Work Unit.* Yale University Press, New Haven, CT and London, 1984. pp.1-177.
2. **Cohen MS,** Hitchcock P, and Hook E, eds. *Sexually Transmitted Disease, Infectious Disease Clinics of North America, Vols. I and II.* 7 (4):1993.
3. **Cohen MS,** Hitchcock P, and Hook E (eds). *Sexually Transmitted Disease, Infectious Disease Clinics of North America, Vol. II.* December 7:4, 1994.
4. Holmes KK, Sparling PF, Mardh PA, Lemon S, Stamm W, Piot P, Walsserheit J, and **Cohen MS.** *Sexually Transmitted Diseases, 5th ed.* McGraw Hill Publishers (in preparation).

Book Chapters

1. Adams DO, **Cohen MS,** and Koren HS. Activation of mononuclear phagocytes for cytotoxicity: Parallels and contrasts between direct tumor cytotoxicity and antibody dependent cytotoxicity. In: *Macrophage activation and ADCC,* H.S. Koren (ed.), Marcel Dekker, N.Y., 1983. pp. 342-345.
2. **Cohen MS,** Colleen S, and Mardh P. Mucosal defenses. In: *Sexually Transmitted Diseases,* Holmes, K.K., Mardh, P.A., and Sparling, P.F. (eds.). McGraw-Hill Book Company, New York, 1984. pp. 173-198.
3. **Cohen MS,** Black JR, Proctor RA, and Sparling PF. Host defenses and the vaginal mucosa. In: *Bacterial Vaginosis,* Mardh, P-A and Taylor-Robinson, D. (eds.) Almqvist & Wiksell International, Stockholm, 1984, pp. 13-22.
4. Gray TK, Korach K, Nabell LM, Flynn TC, Gray KM, Dodd RC, Sivam G, Williams M, and **Cohen MS.** Mechanisms of estradiol's actions on bone. In: *Osteoporosis 1984,* Christiansen, J.S. Johansen and B.J. Riis, (eds.), Norhaven A/S, Viborg, Denmark, Vol 1, 1987, pp. 513-51.
5. **Cohen MS** and Britigan BE. The expanded phagocytic respiratory burst: Bacterial competition for oxygen and its stimulation by host factors. In: *The Respiratory Burst,* Sbarra, A.S., and Strauss, S. (eds.) Plenum Press, 1988, pp. 99-116.

6. Weber DJ, Gammon R, and **Cohen MS**. The acutely ill patient with fever and rash. In: *Principles and Practice of Infectious Diseases, Third Edition*, Mandell, G.L., Douglas, R.G., and Bennett (eds.), Churchill Livingstone, New York, 1990, pp. 479-488.
7. **Cohen MS**, Weber RD, and Mardh P-A. Genitourinary mucosal defenses. In: *Sexually Transmitted Diseases*, Holmes, K.K., Mardh, P.-A., Sparling, P.F., Wiesner, P.J., Cates Jr., W., Lemon, S.M., and Stamm, W.E. (eds.), McGraw-Hill Book Company, New York, 1990, pp. 117-127.
8. Serody J and **Cohen MS**. Infection in the immunocompromised host. In: *Infectious Disease in Emergency Medicine*, J.C. Brillman and R.W. Quenzer (eds.), Little Brown, New York, NY. 1992.
9. Adimora A, Sparling PF, and **Cohen MS**. Vaccines for Classic Sexually Transmitted Diseases, In: *Infectious Disease Clinics of North America*, Cohen, M.S., Hook E., Hitchcock, PJ (eds.), W.B. Saunders Company, Philadelphia, PA. 859-876, vol.8, 1994.
10. **Cohen MS** and Heine RP. Mucosal defenses and microbial pathogens of the genital tract. In: *Advances in Host Defense Mechanisms*. Vol. IV., T.C. Quinn, J.I. Gallin, and A.S. Fauci (eds.), Raven Press, New York, NY 1992, pp.39-55.
11. **Cohen MS**. Mucosal defenses and HIV. In: *AIDS and Human Reproduction*. F. Melica (ed.), Springer-Verlag, New York, NY 1992 pp. 61-9.
12. **Cohen MS**. Vaginal Mucosal Defenses. In: *Vaginitis and Vaginosis*, B. Horowitz and P.-A. Mardh (eds.), Wiley-Liss, Inc., New York, NY. 1991, pp. 33-37.
13. **Cohen MS**, Serody J, Britigan BE, Rosen G, and Charniga L.M. Phagocytes: free radicals, lactoferrin and the lactoferrin receptor. *Chemistry, Biology & Medical Aspects*, K.J.A. Davies (ed.), Pergamon Press, New York, NY 1991, pp. 658-62.
14. Hamilton H and **Cohen MS**. Penicillins, Cephalosporins and Monobactams. In: *Pharmacologic Therapeutics*, ed. Paul L. Munson. Springer Verlag, Berlin 1992.
15. Hamilton H, Byron CS, and **Cohen MS**. Cost containment of antibiotics in the intensive care unit. In *Current Topics in Critical Care*. David H. Gremillion (ed.) Lippincott & Co, Philadelphia 1992.
16. Chamulitrat W, Mason RP, and **Cohen MS**. In: *Free radical formation from organic hydroperoxides in isolated human polymorphonuclear neutrophils*. In: K Yagi, M Kondo, E Niki and T. Yoshikawa, eds, Oxygen Radicals. Elsevier Science Publishers B.V., 1992.
17. Weber DJ, Gammon WR, and **Cohen MS**. The acutely ill patient with fever and rash. In: GL Mandell, JE Bennett, R Dolin, eds, In *Principles and Practice of Infectious Diseases*. Churchill Livingstone Inc, New York, NY 1995.
18. Sparling PF, Elkins C, Wyrick PB, and **Cohen MS**. Vaccines for bacterial sexually transmitted infections: A realistic goal? In: *Infectious Diseases in an Age of Change: The Impact of Human Ecology and Behavior on Disease Transmission*, Roizman B, (ed.) National Academy Press, Washington, D.C., 1995. pp. 213-233.
19. **Cohen MS**. HIV and STDS: A Symposium. *Postgraduate Medicine*, Sept 1995, Vol 98.
20. Mietzner TS, Thomas CE, Hobbs MM, and **Cohen MS**. Gonococcal Vaccines In *New Generation Vaccines*, MM Levine, GC Graemwood, JB Kaper and GS Cobon, eds Marcel Dekker (in press).
21. Fox KK, Isbey S, Carson C and **Cohen MS**. Urethritis, Epididymitis, Orchitis and Prostatitis in *Clinical Infectious Diseases: A Practical Approach*. Eds R. K Root, W. Stamm, F. Waldvogel, Oxford University Press.
22. Fox KK and **Cohen MS**. Gonococcal and Chlamydial Urethritis in *Infectious Diseases*. D Armstrong and J Cohen, eds, Mosby.

23. **Cohen MS** and Anderson D. Genitourinary mucosal defenses. In: *Sexually Transmitted Diseases*, Holmes KK, Mardh PA, Sparling PF, Wiesner PJ, Cates W. Jr., Lemon SM, and Stamm WE (eds.) McGraw-Hill Book Company, New York, 1990, 2000.
24. Musher D, **Cohen MS**, and Baker, C. Immune responses to extracellular bacteria. In: *Clinical Immunology: Principles and Practice* (vol 1), pp 479-502. Rich, R, Fleisher, TA, Schwartz, BD, Shearer, WT, Strober, W (eds.) Mosby-Year Book, Inc, 1996.
25. **Cohen MS**, Dallabetta G, Holmes KK, and Cates W. Global Prevention of HIV Transmission. In: *The Medical Management of AIDS*. W.B. Saunders Company , 1999, Pp. 499-512.
26. Fiscus SA and **Cohen MS**. Collection and processing of seminal plasma for the quantitation of HIV-1 RNA by NASBA and RT-PCR. In: *Sexually Transmitted Diseases: Methods and Protocols*, Peeling RW and Sparling PF, eds. Humana Press, 1998.
27. Ruiz, MS, Ed. No Time To Lose: Getting More From HIV Prevention. Washington, D.C.: National Academy Press, 2001.
28. **Cohen MS** and Hosseinipour, M. HIV treatment meets prevention: antiretroviral therapy as prophylaxis. *AIDS in the 21st Century*. Mayer and Pizer (eds) In *The AIDS Pandemic: Impact on Science and Society*, Elsevier 2004.
29. **Cohen MS**. Approach to the Patient with STDs. *Cecil Textbook of Internal Medicine* (2011, 2014).
30. Del Rios C and **Cohen MS**. Prevention of HIV Infection. *Cecil's Textbook of Internal Medicine* 2014.
31. Goldman-Cecil Medicine, 285. Swygard, Heidi; Cohen, Myron S. Published January 1, 2016. Pages 1876-1881.e2
32. Holmes CB, Hallett TB, Walensky RP, Bärnighausen T, Pillay Y, **Cohen MS**. Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV. In: *Disease Control Priorities: Major Infectious Diseases* (vol 6), pp 91-111. Holmes K.K., S. Bertozzi, B.R. Bloom, and P. Jha, (eds.) World Bank, 2017.
33. Weber D, Juliano J, **Cohen MS**. The Acutely Ill Patient with Fever and Rash. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, edited by Drs. Bennett, Dolin, and Blaser. Jan 2018.
34. Smith MK, Jewell BL, Hallett TB, **Cohen MS**. Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. In: *HIV Vaccines and Cure: The Path Towards Finding and Effective Cure and Vaccine* (vol 1075), pp 125-162. Zhang L., Lewin S.R. (eds.) Springer, 2018.
35. Holmes CB, Hallett TB, Walensky RP, Bärnighausen T, Pillay Y, **Cohen MS**. Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV. *Major Infectious Diseases*. 3rd edition. Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov. Chapter 5.

Review Articles

1. **Cohen MS**, Zakhireh B, Metcalf JA, and Root RK. Neutrophil function in patients receiving carbonate. In: *Lithium Effects on Granulopoiesis and Immune Function*. Rosof, A. and Robinson, W. (eds.), Plenum Press, New York, N.Y. 1980.
2. Root RK and **Cohen MS**. Microbicidal mechanisms of phagocytic cells. *Rev Infect Dis* 3:565-590, 1981.

3. **Cohen MS.** Epidemic hemorrhagic fever revisited. *Rev Infect Dis* 4:992-998, 1982.
4. **Cohen MS.** Antibiotic Therapy: Issues and Perspectives. *Today's Therapeutic Trends* 1:13-28, 1984.
5. Britigan BE, **Cohen MS**, and Sparling PF. *Neisseria gonorrhoeae*: A model of molecular pathogenesis. *N Engl J Med* 312:1683-1694, 1985.
6. Gray TK and **Cohen MS.** Vitamin D, phagocytic differentiation, and immune function. *Surv Immunol Res* 4:200-212, 1985.
7. **Cohen MS.** Antibiotic therapy, cost containment, and the price of tea in China. *Medical Times*. 113:24-28, 1985.
8. **Cohen MS**, Black JR, Proctor RA, and Sparling PF. Host defenses and vaginal mucosa: A reevaluation. *Scand J Urol and Nephrol*. 86:13-22, 1985.
9. Britigan BE, **Cohen MS**, and Rosen GM. Criteria for the detection of free radicals formed by phagocytes using spin trapping. *J Leuk Biol* 41:349-362, 1987.
10. **Cohen MS**, Britigan BE, Hassett DJ, and Rosen GM. Phagocytes, O₂ reduction, and hydroxyl radical. *Rev Inf Dis* 10:1088-1096, 1988.
11. **Cohen MS**, Britigan BE, Hassett DJ, and Rosen GM. Do human neutrophils make hydroxyl radical? Evaluation of an unresolved controversy. *Free Rad Bio* 5:81-88, 1988.
12. Hassett DJ and **Cohen MS.** Bacterial adaptation to oxidative stress: Implications for pathogenesis and interaction with phagocytic cells. *FASEB J* 3:2574-2582, 1989.
13. Rosen GM, **Cohen MS**, Britigan BE, and Pou S. Application of spin traps to biological systems. *Free Rad Res Comm* 9:187-196, 1990.
14. **Cohen MS**, Britigan BE, Pou S, and Rosen GM. Application of spin trapping to human phagocytic cells: Insight into conditions for formation and limitation of hydroxyl radical. *Free Rad Res Comm* 12-13, 17, 1991.
15. **Cohen MS.** Phagocytes in health and disease. *Current Opinion in Inf Dis* 4:338-343, 1991.
16. **Cohen MS** and Sparling PF. Mucosal infection with *Neisseria gonorrhoeae*. *J Clin Invest* 89:1699-1705, 1992.
17. Alcorn TM and **Cohen MS.** Gonococcal pathogenesis: Adaptation and immune evasion in the human host. *Curr Opin Infect Dis*. 7(3):310-316, 1994.
18. Sparling PF, Elkins C, Wyrick PB, and **Cohen MS.** Vaccines for bacterial sexually transmitted infections: A realistic goal? *Proc Natl Acad Sci USA* 91:2456-63, 1994.
19. **Cohen MS.** Molecular events in the activation of human neutrophils for microbial killing. *Clin Infect Dis* 18(Supl 2):S170-9, 1994.
20. Adimora AA, Sparling PF, and **Cohen MS.** Vaccines for classic sexually transmitted diseases. In: *Sexually Transmitted Diseases in the AIDS Era: Part II. Infect Dis Clinics N Am.* **Cohen MS**, Hook EW, Hitchcock PJ (eds.)vol. 8, 1994.
21. Rosen GM, Pou S, Ramos CL, **Cohen MS**, and Britigan BE. Free radicals and phagocytic cells. *FASEB Feb.* 1995.
22. **Cohen MS.** HIV and sexually transmitted diseases: the physician's role in prevention. *Postgrad. Med.* 98(3):52-8, 63-4, 1995.
23. **Cohen MS**, Henderson GE, Aiello P, and Zheng H. Successful eradication of sexually transmitted diseases in the People's Republic of China: implications for the 21st century. *J Infect Dis* 174 suppl 2:S223-9, 1996.

24. Vernazza P, Eron J, Fiscus S, and **Cohen MS**. Sexual Transmission of HIV: Infectiousness and Prevention. *AIDS* 13:155-166, 1999.
25. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, and **Cohen MS**. Antiretroviral Drug Concentration in Semen: Implications for Sexual Transmission of HIV-1. *Antimicrobial Agents and Chemotherapy* 43(8):1817-1826, 1999.
26. Blocker ME and **Cohen MS**. Biological approaches to the prevention of sexual transmission of human immunodeficiency virus. *HIV/AIDS* 14(4): 983-999 December 2000.
27. Hosseinipour M, **Cohen MS**, Vernazza PL, and Kashuba AD. Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? *Clin Infect Dis.* 34; 1391-5, 2002.
28. **Cohen MS**, Hossenipour M, Butera S, and Kashuba AA. Antiretroviral therapy to prevent sexual transmission of HIV In *Current Clinical Topics in Infectious Disease*, Remington J and Swarz, M (eds) 2002.
29. Galvin SR and **Cohen MS**. Sexual transmission of HIV. *Nature Reviews Microbiology* January 2: 33-42, 2004.
30. Pilcher CD, Eron, JJ, Galvin S, Gay C, and **Cohen MS**. Acute HIV Revisited: New Opportunities for Treatment and Prevention. *J. Clin Invest* 113: 937-945, 2004.
31. **Cohen MS**. Amplified transmission of HIV-1: New clues to the AIDS pandemic. *Tran Am Clin Climatol. Assoc.* 117:213-225, 2006.
32. Lin C, Gao X, Chen XS, Chen Q, and **Cohen MS**. China's syphilis epidemic: a systematic review. *STD* 33: 726, 2006.
33. Gay, CL and **Cohen MS**. Antiretrovirals to prevent HIV infection: Pre and Postexposure prophylaxis. *Curr. Infect. Dis. Rep.* 4: 323-31, 2008.
34. Kumi Smith M, Jewell BL, Hallett TB, **Cohen MS**. Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. *Adv Exp Med Biol.* 2018;1075:125-162. Review. PMID: 30030792.